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1 INTRODUCTION
1.1

Obesity Epidemic and the Rise of Metabolic Disease.
The prevalence of obesity in the United States has risen dramatically in the

last several decades. The Centers for Disease Control and Prevention (CDC)
reported in 2011 that over a third of the adult population was obese, a sharp rise
since 1985, when obesity rates in most US states were below 10% [1]. Moreover,
recent analyses suggest that the body mass index (BMI) measure used to diagnose
obesity in these reports may underestimate the prevalence of obesity. BMI,
calculated as body mass in kilograms divided by height in meters squared, does not
take into account body composition. As a result, individuals with diminished muscle
weight, in particular elderly women, are commonly misclassified as not obese [2].
The reverse misclassification of individuals with high muscle mass, such as athletes,
as overweight (25<BMI<30) or obese (BMI>30) also occurs, but the overall effect
of the use of the BMI system in the general population is an underestimation of
obesity prevalence. Based on these findings, alternative age-specific BMI cutoffs
have been proposed, and by these new criteria the prevalence of obesity is even
higher, about two-thirds [3]. Regardless of the metric used, the rising rates of
obesity have led to its recognition in the US as an epidemic.
Obesity is a significant risk factor for a host of metabolic and cardiovascular
disorders, and in particular it is highly associated with type II diabetes. The CDC
reports a steep rise in the prevalence of diagnosed diabetes in the US that is
concomitant with the obesity epidemic, up from 3.5% in 1980 to 9.1% in 2010, and
predicting a continued increase [4]. This statistic holds true in the age-adjusted
model as well, indicating that the increase in diabetes prevalence is independent of
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the aging of the population. The inability to clear glucose from the bloodstream in
diabetic individuals leads to microvascular and macrovascular complications,
multiple end-organ damage and increased morbidity and mortality. Furthermore,
insulin resistance is often associated with hypertension and dyslipidemia as part of
the metabolic syndrome, leading to additional health risks. As a result, the toll from
the obesity and diabetes epidemic on public health and healthcare spending is vast,
and research to understand the mechanisms behind metabolic syndrome-related
diseases is an important ongoing effort.

1.2

Nuclear Receptors in Metabolic Regulation.
Energy metabolism at the cellular levels is regulated in large part by the

gene transcription activity of nuclear receptors. The nuclear receptor superfamily
includes steroid hormone receptors, peroxisome proliferator-activated receptors
(PPARs), thyroid hormone receptor, retinoic acid receptor and a number of others,
as well as some orphan nuclear receptors with unidentified ligands. The
characteristic feature of hormone receptors is their capacity to bind specific ligands,
recognize and bind specific regulatory DNA sequences, and interact with gene
transcription coregulators. Through these mechanisms nuclear receptors respond to
changes in the extracellular environment, which are signaled by specific ligands,
often hormones, and regulate the gene transcription program of the cell to adjust
to these changes. Different types of nuclear receptors act by slightly different
mechanisms. Type I, including the sex hormone receptors and the glucocorticoid
receptor, dissociate from cytoplasmic heat shock proteins upon ligand binding,
translocate

into the nucleus and bind to hormone response elements as
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homodimers [5]. PPARs are type II nuclear receptors, which are bound to DNA as
heterodimers with the 9-cis-retinoic acid receptor (RXR), and recruit transcription
corepressors to the local chromatin [6] (Figure 1). In the presence of ligands, the
receptor undergoes a conformational change which alters its interaction with ATPdependent chromatin remodeling and histone modifying enzymes, such as nuclear
receptor corepressors NCoR and SMRT, BRG-1 associated factor (BAF) family,
nuclear receptor coactivators SRC-1, the p300-CBP coactivator family and the
mediator complex [7-9]. This transcriptionally active conformation favors the
release of corepressors and recruitment of transcription coactivator complexes
including histone acetyltransferases, altering the histone acetylation pattern and
increasing transcription of nearby genes. The nuclear receptor and its associated
protein complex cycle on and off the DNA molecule and are degraded by the
proteasome as part of a carefully controlled transcriptional regulation equilibrium
[10].
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Figure 1. Schematic Representation of Transcription Regulation by Type II
Nuclear Receptors.
Ligand binding induces a switch from gene repression (top panel) to activation
(bottom panel). Some representative members of the coactivator and
corepressor complexes are shown. Chromatin marks associated with repressed
and activated states are indicated. Adopted from Rosenfeld et al. [11].

All nuclear receptors have homologous domains for DNA binding and ligand
binding, separated by a hinge [12]; PPARs also share an N-terminal domain that is
adjacent to the DNA binding domain [13]. The ligand binding domain is comprised
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of several α-helices that create a ligand pocket and contain transcription
coregulator interaction surfaces. Structurally, the DNA-binding domain is comprised
of two zinc finger motifs. The “knuckle region” at the base of zinc finger one
contains the six-amino-acid “P-box” (Figure 2). This is the region of the receptor
that fits into the major groove of the DNA molecule and is important for the
recognition of DNA binding sites [14-17]. The binding sites, or response elements,
are cis-acting regulatory DNA sequences that are located within the promoters,
gene coding sequences, or up to 100,000 base pairs away from the transcription
start sites of the receptor target genes [18-20]. The response elements are
receptor-specific; they are often direct or inverted repeats of a short base pair
sequence with a variable number of spacing nucleotides. However, each receptor
can recognize many deviations of its response element from the consensus
sequence - a versatility that enables one receptor to regulate hundreds of genes.
Moreover, it has been observed that there is a high degree of evolutionary
conservation between the same response element in different species [21],
indicating that the DNA sequence from which a nuclear receptor regulates the
expression of a particular gene is of non-trivial importance. However, exactly how
the interaction between a receptor and its DNA binding site directs subtle changes
in gene transcription is not presently clear.
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Figure 2. Schematic Representation of the Domain Structure of PPARγ.
Bottom panel shows conserved nuclear receptor domains: AF, activation
function; DBD, DNA-binding domain; LBD, ligand-binding domain. Top panel
represents the zinc finger structures in the DNA binding domain, with the p-box
amino acids shaded and glutamate 157 shown in boldface. Adopted from Temple
et al. [22].

PPARs

are

nuclear

receptors

that

have

evolved

to

regulate

energy

homeostasis by recognizing various fuel molecules as signals of metabolic changes
in the body. PPARα, β/δ, and γ are isotypes of the PPAR family with unique tissue
expression profiles and roles in metabolic regulation. PPARα is expressed most
abundantly in the skeletal muscle and the liver, and functions to promote fatty acid
oxidation. PPARβ/δ is expressed ubiquitously and is involved in the regulation of
circulating lipoprotein particles [23]. PPARγ is expressed in multiple tissues, but
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most abundantly in adipose, and is a potent promoter of insulin signaling,
adipogenesis and lipid storage.

1.3

PPARγ is a Central Player in Energy Metabolism.
PPARγ entered the spotlight as a major player in metabolic regulation in the

early 1990s [24] through the discovery of thiazolidinediones (TZDs) as potent
synthetic insulin-sensitizing drugs. TZDs quickly passed clinical trials and became
front-line agents in the treatment of type II diabetes for their robust glucoselowering action, although their popularity has recently decreased due to safety
concerns. The TZD prototype troglitazone, which has since been withdrawn for
idiopathic hepatotoxicity, was shown to be a ligand activator of PPARγ, spurring an
in-depth investigation of this receptor, which revealed its activity as a potent
inducer of adipocyte differentiation [25]. Many synthetic PPARγ ligands, both TZDs
and other classes, are thoroughly characterized and widely used both in the clinic
and in basic science. Endogenous PPARγ ligands are less well known, but thought to
be certain fatty acid metabolites, such as 15-deoxy-12,14-prostaglandin J2 [2628], an intermediate in the arachidonic acid metabolism pathway.
Activation of PPARγ results in systemic insulin sensitization through complex
mechanisms involving multiple organs. In the adipose tissue, PPARγ promotes lipid
uptake and storage, increases the number of smaller adipocytes and recruits
alternatively activated macrophages, resulting in a more plastic, less inflammatory
adipose phenotype which acts as a better buffer of circulating lipids and reduces
ectopic lipid accumulation. In the skeletal muscle, PPARγ potentiates insulin action,
and in the liver it acts to suppress gluconeogenesis, altogether leading to lower
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blood glucose levels. In addition to its central role in energy homeostasis, PPARγ
has been recognized for its anti-inflammatory [25, 29-33] and anti-tumorigenic
[34] activities. The former has been attributed in part to PPARγ-mediated
downregulation of macrophage inflammatory cytokines and induction of the
alternative macrophage phenotype. The latter is most likely due to a general prodifferentiation and anti-proliferation effect of PPARγ. Other areas of demonstrated
PPARγ involvement include bone metabolism [35-37], nerve myelination [38],
reproduction [39, 40], atherosclerosis and cardiovascular disease [25].
The PPARγ gene is expressed via alternative mRNA splicing into four
transcript variants, each controlled by a separate promoter, which are translated
into two distinct protein isoforms [41]. PPARγ1 (477 amino acids in the human) is
expressed in a variety of tissues but most abundantly in the liver, muscle, intestine,
and kidney [42]; PPARγ2 (505 amino acids in the human), which includes an
additional 30-amino acid sequence at the N terminus, is expressed almost
exclusively in adipocytes [43]. The two isoforms behave similarly in gene
transcription and DNA binding assay, with minor differences in adipogenic potential
and ligand responsiveness [44, 45].
Genome-wide DNA binding site analyses have confirmed the consensus PPAR
response element (PPRE) as a direct repeat sequence with a single spacing
nucleotide (DR1): AGGTCA A AGGTCA [19, 20]. As other type II nuclear receptors,
PPARγ binds DNA as a heterodimer with RXR [46, 47]; however, the orientation of
the heterodimer on the PPRE is reversed compared to other RXR-binding nuclear
receptors: PPARγ makes contact with the 5’ half of the PPRE, while RXR binds to the
3’ half [48, 49].
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Comprehensive sets of PPARγ target genes in adipocytes have been
generated using mRNA profiling and ChIP-seq approaches [50-52]. During
adipogenesis, PPARγ induces a gene transcription program consisting of several
thousand genes that are involved in adipocyte differentiation, intracellular lipid
metabolism, insulin signaling and other pathways. The PPREs from which PPARγ
regulates the expression of many of its genes have been identified and confirmed in
in vitro studies, and present a useful tool for studying the interaction of PPARγ with
its DNA binding sites. The DNA binding affinity of PPARγ varies between different
PPREs, however it is not clear what the determinants of this target DNA selectivity
are; it appears that deviation of the PPRE from consensus is not the only factor,
and may not play a role at all [53]. Furthermore, there has been some debate on
the validity of the current PPRE consensus, and proposals of expanding it to include
the 5’ flanking nucleotides due to some evidence that PPARγ binding to its half-site
is flexible, while the five nucleotides directly adjacent to the half site may be
important for this binding, as may also be the spacing nucleotide [22, 49, 53]. Lack
of recent studies involving the broad spectrum of PPREs further contributes to the
present gaps in understanding of the selectivity of PPARγ/PPRE interaction.
While the molecular biology of PPARγ has been studied in detail, there are
still large gaps in our understanding of how PPARγ transcriptional activity results in
the wide-spectrum physiological changes in vivo. Genetic mutations in the PPARγ
gene that cause clear diabetes-related phenotypes, such as the E157D mutation
that is the subject of this dissertation, present a unique opportunity to develop a
better understanding of the molecular mechanisms mediating the role of PPARγ in
maintaining energy homeostasis and the development of metabolic disease.
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1.4

Human PPARγ Mutations and Familial Partial
Lipodystrophy.

1.4.1 General Characteristics of Familial Partial
Lipodystrophy.
Human mutations in the PPARγ gene occur with a low frequency (estimated
1:100,000 in populations of North-European descent [54], but cause a severe
metabolic phenotype called familial partial lipodystrophy (FPLD) type III [55].
These mutants act by a variety of mechanisms biochemically (discussed below), but
all are inherited in a dominant pattern. Individuals with FPLD are phenotypically
normal until puberty, when subcutaneous adipose tissue in the extremities is
depleted, leading to a characteristic sharply-defined appearance of the limb
musculature. At the same time, visceral central fat depots in the regions of the
abdomen, shoulders, upper back, neck and occasionally the face become enlarged,
and fatty infiltration of the liver and skeletal muscle is apparent on MRI [54]. It is
not clear what induces this change, but there is likely to be increased adipose tissue
remodeling during puberty, a process that apparently goes awry in the absence of
two healthy copies of the PPARγ gene. Visceral adipose tissue is more lipolytic and
inflammatory than subcutaneous fat, and is associated with metabolic syndrome,
and this association is especially pronounced in FPLD patients, who develop insulinresistant diabetes as early as in their 20s. Consistent with insulin resistance and
adipose tissue dysfunction, biochemical evaluations show elevated plasma levels of
glucose, insulin, C-peptide, triglycerides and glycosylated hemoglobin, as well as
decreased HDL and adipose-derived insulin-sensitizing hormones leptin and
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adiponectin [56-62]. In one case report, a lamin A mutation lead to the
development of severe insulin resistance without the other abnormalities typically
observed in FPLD [63], suggesting that insulin resistance may be an initial step in
the development of FPLD, as it is in diabetes. In addition to lipodystrophy and
diabetes, FPLD often includes hypertension, dyslipidemia, acanthosis nigricans and
polycystic ovary syndrome with hirsutism in the females - all components of the
metabolic syndrome [64]. Hypertriglyceridemia leads to the development of hepatic
steatosis, pancreatitis and eruptive xanthomas; vascular complications of diabetes
are observed, including neuropathy, retinopathy, nephropathy, and secondary
atherosclerosis. Notably, the management of lipodystrophies is similar to diabetes,
focusing on control of hyperglycemia, lipid lowering, and a low-fat diet; moreover,
thiazolidinediones have been shown to improve metabolic function in lipodystrophy
patients and preferentially increase subcutaneous fat stores [65, 66].
Although FPLD is a rare disease, it presents a useful model to improve the
understanding of adipose tissue and the metabolic syndrome - an association that,
as discussed above, is plainly evident from public health data, but poorly
understood on a mechanistic level. In this model, a disruption of a single
transcription factor - PPARγ - results in a severe and well-defined metabolic
phenotype that closely resembles the common form of multi-factorial type II
diabetes, but presents in a more exaggerated way. For this reason, FPLD III has
been accepted as a monogenetic model of diabetes [67], and has been studied
extensively, lending a large contribution to our current knowledge of the role of
PPARγ in energy homeostasis and metabolic disease.
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1.4.2 Known FPLD mutations.
More than a dozen naturally-occurring mutations in the human PPARγ coding
region have been identified and reported as case studies [56-59, 61, 62, 68-73];
many of these have been examined on a molecular level by our group and others.
These include single amino-acid substitutions and non-sense mutations in the
ligand binding domain and the DNA binding domain, as well as frameshift mutation
that results in a deletion of the DNA binding domain. In addition, two common
polymorphisms have been identified within the PPARγ gene which confer modest
protection from insulin resistance [74-78]. The molecular mechanisms by which
these mutants disrupt PPARγ transcriptional activity are diverse: some of the
ligand-binding domain mutants are dominant negative by way of binding the DNA
and failing to induce transcription (V290M, Y355X, P467L); some have impaired
transactivation without dominant negative activity (F388L, R425C). Among the DNA
binding domain mutants, the loss of function can be accompanied by dominant
negative activity in a non-DNA-binding mechanism (C114R, C131Y, C152W), or not
(C190S, R194W). Considering the complex structure-function relationship of the
PPARγ protein, including the zinc fingers in the DNA binding domain and the
intricate spatial organization of helices in the ligand binding domain, it is not
surprising that mutations in different regions of the molecule affect PPARγ activity
by such a variety of mechanisms. However, any disruption in the receptor function
reported to date, regardless of the molecular mechanism, has resulted in the typical
FPLD presentation.
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1.5

E157D PPARγ Cohort.

1.5.1 Unique Clinical Presentation of the E157D PPARγ
Cohort.
The E157D mutation was discovered in a large French-Canadian kindred by
clinical collaborators of our research group, Drs. Gagne, Campeau and Hegele. FPLD
features were identified in the proband on a clinic visit for severe dyslipidemia;
family history revealed similar appearance in many relatives. After a thorough
clinical investigation of multiple family members and DNA sequencing, a diagnosis
of FPLD caused by a novel PPARγ mutation, E157D, was made. Heterozygous family
members are affected with the characteristic partial lipodystrophic fat distribution,
have early-onset insulin-resistant diabetes, hypertriglyceridemia often complicated
by pancreatitis, hypertension, and PCOS in several women. In addition, this FPLD
cohort is unique for presenting with several abnormalities not previously associated
with FPLD type III cases: there is an increased prevalence of neuromuscular and
hematological

abnormalities

such

as

tinnitus,

carpal

tunnel

syndrome,

pancytopenia, bone fractures and myalgias. It has been noted that the small sizes
of mutant PPARγ cohorts reported to date have limited our ability to draw
meaningful

conclusions

about

the

relative

severity

of

dominant

versus

haploinsufficient genotypes, as well as the relative environmental contribution to
the disease presentation [69]. The E157D PPARγ cohort spans three generations
and includes fifteen affected individuals (Figure 3) - by far the largest FPLD cohort
known to date, affording an unprecedented opportunity to examine the effects of a
single PPARγ mutation with some statistical power.
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Figure 3. Family Tree of the E157D PPARγ Cohort.
Filled-in shapes represent individuals heterozygous for the mutation. Clinical
presentations of study participants are summarized.
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1.5.2 Potential implications of the p-box mutation.
The E157D PPARγ mutation is not only unique in its clinical phenotype but
also on a molecular level. The amino acid substitution is localized to the p-box of
the receptor (indicated in boldface in Figure 2) - a region comprised of only six
amino acids that is notable for its importance in the interaction of the receptor with
DNA and binding site selectivity, as described above. The p-boxes of various
nuclear receptors have been studied in detail. The sequence of the PPARγ p-box is
identical to those of its close evolutionary relatives, the thyroid hormone and
retinoic acid receptors, while other receptors have evolved to have slightly or
significantly different p-box sequences [79, 80]. This diversity is believed to be
important for the ability of different nuclear receptors to recognize their cognate
DNA binding sites. The E157D PPARγ mutation is the first reported case of a
naturally-occurring p-box mutation in PPARγ. However, synthetic p-box mutations
in PPARγ have been made by site-directed mutagenesis with the goal of
investigating the role of these amino acids in DNA binding site recognition [22]. In
this in-vitro study, alanine substitutions at positions 157 and 158 of the receptor
did not abolish its ability to bind PPREs and activate gene transcription. However,
the mutation changed the relative affinity of PPARγ for various PPREs, and this
change was mirrored by transcriptional activity levels on the different PPREs. The
E157D mutation is a more conservative substitution that the alanine mutations
studied in vitro by Temple et al: the negative charge of the side chain is preserved,
and the only difference is one unit of the carbon chain. We therefore reasoned that
it is unlikely to dramatically affect the ability of the receptor to bind DNA, but more
likely acts via a subtle mechanism such as observed by Temple et al, altering the
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DNA binding site selectivity of PPARγ. We postulated a hypothesis that the E157D
mutation causes lipodystrophy and diabetes by altering the target gene selectivity
of the receptor. We expected to find a small set of genes that was misregulated by
E157D PPARγ, revealing novel genes of interest for diabetes pathophysiology.
Hence, this subtle, naturally-occurring PPARγ p-box mutation that causes a severe
metabolic phenotype was promising to be a valuable tool for gaining insight into
how PPARγ interacts with the DNA what molecular pathways are involved in its
regulatory role in energy homeostasis.
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2 MATERIALS AND METHODS
2.1

In-Silico Structure Prediction.

2.1.1 SIFT.
Sorting Intolerant from Tolerant (SIFT) is a method for predicting the effect
of a mutation on protein function by assessing its degree of conservation in
homologous proteins, and has been shown to be fairly accurate in identifying
mutations which have a strong phenotype [81]. The identity of the residue and its
chemical properties (eg, if it’s always hydrophobic) are factored into the score.
Therefore, a change in a highly conserved region is predicted to affect protein
function. The protein sequence of E129D PPARγ1 was analyzed by SIFT Human
Protein [82] in order to predict whether the substitution would have a major effect
on the protein function.

2.1.2 Swiss-Model.
The structure of E157D mutant PPARγ was modeled using Swiss-Model [83].
The crystal structure of rosiglitazone-bound PPARγ1-RXRα-PPRE complex (PDB ID
3dzy, [84] was loaded into Swiss-Pdb viewer [85] as template, and glutamate 129
was changed to aspartate to represent the E157D mutant. Both the wild-type and
mutant complexes were subjected to energy minimization using the GROMOS
algorithm [86]. Hydrogen bond contacts were defined as 1.2 - 2.76 Å with a
hydrogen atom present and 2.195 - 3.3 Å with no hydrogen present.
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2.1.3 MolSoft ICM.
E157D PPARγ segment H122-I144 was used in homology modeling with 3dzy
as template. Global energy minimization and Monte Carlo side chain optimization
[87]; [88] were implemented to predict the folding of the E157D PPARγ segment.
Local energy minimization was used to calculate hydrogen bond distances for E129
(or D129) and C4012 (which corresponds to the third position of the 5’ half site of
the PPRE) with default parameters defining the hydrogen bond.

2.2

Cell Lines and Culture.
NIH3T3 fibroblasts were maintained in Dulbecco’s Modified Eagle’s Medium

(DMEM) supplemented with 10% fetal bovine serum, 100 units/mL penicillin and
100 μg/mL streptomycin, and passaged at sub-confluency.
3T3-L1 fibroblasts were grown to confluence in DMEM with 10% calf serum,
then switched to 10% fetal bovine serum for two days, at which time adipogenic
differentiation was induced as described previously [89].
293FT cells were maintained in DMEM with 10% fetal bovine serum, 0.1 mM
non-essential amino acids, 100 units/mL penicillin, 100 μg/mL streptomycin and
500 μg/mL geneticin.
NLacZ, NPγ1 and NPγ2 cells were maintained as NIH3T3 cells with the
addition of 2μg/mL blasticidin.
10% DMSO was added to freezing medium for all cell lines. Geneticin and blasticidin
were omitted from the medium for the first day after thawing the corresponding cell
lines.
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2.3

Cloning of Plasmids.
Single-stranded oligonucleotides containing PPREs listed in Table 1 with NheI

restriction site overhangs at the 5’ end and XhoI overhangs at the 3’ end were
synthesized by IDT and annealed by slow cooling down from 100ºC in annealing
buffer (10mM Tris pH 8.0, 1mM EDTA, 50mM NaCl). Double-stranded PPREs were
then either biotinylated for the EMSA or inserted into the multiple cloning site of the
pGL3-TK luciferase reporter plasmid (Promega).
Mammalian PPARγ1 expression plasmid (pTR151) was constructed by our lab
previously using the tet-regulated pTRE vector system and contains an N-terminal
double

flag

tag.

The

E157D

mutation

was

introduced

using

site-directed

mutagenesis (Stratagene) according to the manufacturer’s directions using the
following mutated primer: 5’-CACTATGGAGTTCATGCTTGTGACGGATGCAAGGGT-3’
(mutated nucleotide is indicated in boldface and underlined). Wild-type and E157D
PPARγ2 expression plasmids were constructed by inserting the N-terminal unique
segment of PPARγ2, amplified from human adipose cDNA by PCR, into the NcoI site
of pTR151, and the correct orientation of the insert was verified by sequencing.
Lentiviral vectors for stable PPARγ expression were constructed using the Gateway
cloning system (Invitrogen). The Gateway entry clone was generated by inserting
2Xflag-tagged PPARγ1 or PPARγ2 cDNA into the pENTR4 vector, which was then
recombined with the destination vector pLenti6.3/V5-DEST using LR Clonase II to
generate the lentiviral PPARγ expression vectors.
The NCoR1 expression plasmid was generously provided by Dr. Ronald N.
Cohen.
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2.4

Transient Transfection.
NIH3T3 cells were plated to be ~90% confluent the next day in antibiotics-

free medium. On the day after plating, the medium was replaced with a reduced
volume of fresh antibiotics-free medium, and the lipofectamine 2000 transfection
mix was added dropwise. After 12 hours of incubation, lipofectamine complexes
were removed and replaced with fresh antibiotics-free medium. Cells were
harvested 24 hours after the start of transfection.

2.5

Luciferase Transcription Reporter Assays.
For luciferase reporter assays, cells were grown in 12-well plates and each

well was transfected in a total volume of 0.5 mL with the following plasmids: 200
ng of luciferase reporter, 100 ng of pTREshuttle2 vector or PPARγ (γ1 or 2, wildtype or E157D), 50 ng of tet-off, 100 ng of RXRα, 50 ng of β-galactosidase and 200
ng of blue script (pBS) as carrier. The plasmids were mixed in 50 μL of Opti-MEM
and incubated with lipofectamine 2000 (2 μL per well) as instructed by Invitrogen
before the start of transfection. Rosiglitazone (20 μM) or DMSO vehicle control was
added to the media for the duration of transfection. Each transfection condition was
replicated by two wells, and each experiment was repeated three times. At the end
of transfection, the cells were washed with phosphate-buffered saline (PBS) and
lysed with 150 μL of passive lysis buffer (Promega). For the luciferase assay, 20 μL
of the cell lysate were diluted into 100 μL of luciferase assay buffer (15mM KH2PO4
pH 7.8, 15mM MgSO4, 4mM EGTA, 2mM ATP, 1mM DTT) in a white 96-well plate,
then 30 μL of D-luciferin was added for a final concentration of 60 μg/mL. The light
output was quantified immediately using a luminometer, integrated over 10
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seconds. The β-galactosidase assay was used to account for transfection efficiency.
20 μL of the cell lysate were mixed with 30μL of lysis buffer and then with 2X βgalactosidase assay buffer (200mM sodium phosphate pH 7.3, 2 mM MgCl2, 100
mM β-mercaptoethanol, 1.33 mg/mL o-nitrophenyl-β-galactoside). Absorbance at
420 nm was read after 30 minutes at 37°C by the VersaMax microplate reader.
For transcription coregulator interaction assays, NIH3T3 cells were grown
and transfected as above, with the addition of 200 ng of the indicated coregulator
plasmid instead of pBS.

2.6

Electrophoretic Mobility Shift Assays.
The consensus PPRE and ADN PPRE oligonucleotides were biotinylated on the

5’ end by IDT. All other double-stranded PPRE oligonucleotides were labeled with
biotin-dUTP using Klenow DNA Polymerase (Fisher) according to the instructions.
NIH3T3 cells were grown in 100mm plates and transfected with the following
plasmids: 5 μg of pTREshuttle2 or PPARγ1 (wild-type or E157D), 5 μg of RXRα, and
2 μg of tet-off. Nuclear extracts were prepared using the NE-PER kit (Pierce) after
24 hours of transfection. The 20 μL EMSA binding reaction was optimized to contain
1.25 fmol/μL probe, 1 μL nuclear extract, 67 ng/μL poly dI:dC, 1% glycerol, 0.05%
NP-40 and 1 mM MgCl2 in the EMSA binding buffer (Pierce). A 200-fold molar
excess of unlabeled probe was used as competitor. 1 μg of M2-Flag mouse
monoclonal antibody (Sigma) or non-immune mouse IgG (Millipore) was used in
supershift binding reaction. The binding reactions were incubated, separated on a
5% native polyacrylamide gel, transferred onto Biodyne-B membranes and detected
using the Light-Shift EMSA kit (Pierce) as directed by the protocol.
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2.7

Western Blotting.
Whole cell lysates for protein analysis by western blotting were prepared by

washing the cells with PBS, incubating on ice in RIPA buffer for 10 minutes, then
sonicating for a total of 30 seconds in 5-second bursts alternating with cooling the
tube on ice. The lysates were cleared by centrifugation and stored at -80°C. BioRad mini-protean system was used for SDS-PAGE with 20-80 μg of cell lysate per
lane, normalized by measuring the protein concentration using the Bradford assay.
Separated samples were transferred onto a PVDF membrane for blocking and
detection. Primary antibodies used were PPARγ (E-8, Santa Cruz 7273), M2-FlagHRP (Sigma), His-probe (G-18, Santa Cruz 804), TFIID (TBP) (SI-1, Santa Cruz
273), and GAPDH (FL-335, Santa Cruz 25778). Chemiluminescent signal was
detected using the SuperSignal West Dura (Pierce) luminol/peroxide system by the
gel DOC detector.

2.8

Lentivirus Packaging and Infection.
Lentiviral PPARγ expression vectors were grown in Stbl3 competent E.coli

and purified using a plasmid midiprep kit with the addition of 10mM EDTA to the
resuspension buffer in order to inhibit the endonuclease in this endA1+ strain.
293FT cells were grown in 100mm plates and transfected with 9 μg of lentiviral
packaging mix, 3 μg of lentiviral PPARγ expression vector (PPARγ1 to make NPγ1
cells, or PPARγ2 to make NPγ2 cells) and 36 μL of Lipofectamine 2000 in a total
volume of 8 mL of antibiotic-free medium. The control plasmid was pLenti6.3/V5GW/lacZ, supplied with the ViraPower HiPerform Lentiviral Expression Systems kit
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(Invitrogen). Medium was replaced on the day after transfection, and viruscontaining supernatant was collected two days later, clarified by centrifugation and
used directly for infection.
NIH3T3 cells were plated without antibiotics in six-well plates to be ~50%
confluent the following day, when the medium was replaced by virus-containing
supernatant with 4 μg/mL Polybrene (Sigma). The next day, virus-containing
medium was removed and replaced with fresh medium without antibiotics. The
following day, 100 units/mL penicillin, 100 μg/mL streptomycin and 2μg/mL
blasticidin were included in the medium to select stable infected cells. The selection
continued for two weeks, during which time the cells were passaged normally. At
the end of selection, frozen stocks of NPγ1, NPγ2 and NLacZ cells were prepared
and used for all subsequent experiments to control for transgene expression, which
we have observed to decrease over transgenic cell passages.

2.9

Reverse Transcriptase PCR.
Cells were grown in 6-well plates and, when indicated, treated with 20 μM

rosiglitazone or DMSO vehicle for 24 hours, then washed with PBS and harvested in
1 mL of TRI Reagent (Sigma). RNA was isolated with 1-bromo-3-chloro-propane
and precipitated with isopropanol as instructed by Sigma, washed with 70%
Ethanol, resuspended in 50 μL of RNase-free water,

and stored at -80°C. RNA

quality for reverse transcription and PCR was confirmed by the ratio of UV
absorbance at 260/280 nm, quantified by Nanodrop, which ranged between 1.91
and 2.02. cDNA was made from 2 μg (100 ng/μL) of total RNA using the High
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Capacity

Reverse

Transcriptase

kit

(Applied

Biosystems),

according

to

the

manufacturer’s instructions.
Genes that were upregulated in NIH3T3 cells by lentivirus-infected PPARγ in
previously published work [90], either specifically or by more than one PPAR
species, were selected for qPCR analysis. PCR primers were designed and verified
for specificity in the mouse transcriptome using Primer-BLAST (NCBI) with obligate
inclusion of an intron in the PCR product and, when possible, an exon junction
within the primer sequence. Primer sequences are listed in Table 1. Gene
expression was analysed by end-point PCR using the Amplitech Gold DNA
polymerase kit, or by quantitative PCR using ABsolute Blue QPCR CYBR Green Low
Rox mix (Thermo Scientific), with 2 μL of the cDNA-containing product as template.
End-point PCR products were separated by electrophoresis on a 2% agarose gel
and visualized by ethidium bromide UV fluorescence. qPCR products were
synthesized and detected using the Stratagene MX3000P thermocycler, and
assessed for the presence of nonspecific amplification by multiple absorbance
peaks; minimum threshold of detection was determined automatically. Gene
expression was normalized to PPIA as the internal control using the 2-ΔΔCT method
[91].
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Table 1. PCR Primers for Measurement of PPARγ Target Gene Expression.
*, Primers do not amplify human PPARG cDNA; PCR product spans two introns
**, Primers amplify both the human and mouse PPARG cDNA; no introns in the PCR product

Gene

PCR

Primer

product

spans exon

symbol

Forward primer

Reverse primer

size, bp

junction

Fabp4

CCCTCCTGTGCTGCAGCCTT

GTGGCAAAGCCCACTCCCACT

148

yes

Adipoq

AGGGAGAGAAAGGAGATGCAGGTCT

ACAGTGACGCGGGTCTCCAG

181

yes

Cd36

TGTGGAGCAACTGGTGGATGGT

CGTGGCCCGGTTCTACTAATTCATGC

148

yes

Plin4

AGACTGCCACCTCCAGCCCC

TCCGGGCAGAGCTGAAGCCA

133

yes

Pcx

GGTGCTTGGCTGGTACAAGATGC

CGCCGGACATTTGGGGAGGC

111

yes

Pla2g16

AGCAAAGGCATCCACGCTGC

CTGCCCCAGCTCCTGCGATT

198

yes

Cpt2

GAAGCAGCGATGGGCCAGGG

CAGGGGCAAAGCCACCGAGG

181

yes

Acox1

TGCTGCAGACGGCCAGGTTC

GGCCAGACTGCCACCTGCTG

133

yes

Hsl

AGGCCTCAGTGTGACCGCCA

GCAGGCGGCTTACCCTCACA

200

yes

Facl2

TGCCTGAGCTTGCCCGGAGA

ACACACCTCACCCTCGCCCT

126

yes

mPPARG*

ACGGGGTCTCGGTTGAGGGG

TCCGAAGTTGGTGGGCCAGA

182

no

PPARG**

CTCCAGCTGAAGCTGAACCAC

AAATGTTGGCAGTGGCTCAG

209

no

Sncg

CAAGGAGCAGGCCAATGCCGT

CCAAGTCCTCCTTGCGCACCAC

125

yes

Mtap2

CAGCCACAGTGGAGGAAGCAGC

GACCTGGTGGTCCGTCGTGC

229

yes

2.10

Chromatin Immunoprecipitation

NIH3T3 cells were grown in 100mm dishes and transfected with expression
plasmids for biotinylated PPARγ (pNBio WT, E157D, 5.5 µg, or empty vector, 4.5
µg), RXR (1 µg), tet-off (1 µg), GFP (1 µg), and the empty pNBio vector (3.5 µg),
mixed with 36 µL Lipofectamine 2000. Cells were incubated with 25 uM biotin for 48
hours, then crosslinked in 1% formaldehyde and harvested. Chromatin was sheared
using the Branson 450 digital sonicator in repeated 15-second bursts optimized to
yield 500-1000 bp-long DNA fragments, then precipitated with streptavidin-coated
beads, washed and eluted as previously described [92]. Input and precipitated DNA
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samples were analyzed by PCR using primers for the mouse aP2 PPRE region
(forward: 5'- GCC ATG CGA CAA AGG CAG AAA -3', reverse: 5'- GTG TTT GGG CTG
TGA CAC TTC C -3'), mouse adiponectin promoter spanning the region that is
aligned with the human PPRE (forward: 5’-CTT ATG GGA AAG GGA GGT CTC C-3’,
reverse: 5’-AAT AGC CAA TGA GTG GGC CC-3’), and a control region downstream
of the aP2 gene which contains no known PPREs (forward: 5’-CTG TCC CCT GTA
CAC CGT CT-3’, reverse: 5’-TCT CTT GGA ACT GGT AGC GCA G-3’).

2.11

Microarray Analysis of Gene Expression.

NPγ2WT and NPγ2E157D cells were grown in 6-well plates and treated with
20 μM Rosiglitazone or DMSO vehicle for 24 hours. NPγ2 cells were thawed from
frozen stocks for three independent experiments. Total RNA for microarray
hybridization was isolated as described above, purified on RNeasy columns (Qiagen)
and diluted to 50 ng/μL. RNA integrity measured by Agilent Bioanalyzer 2100
ranged between 7.2 and 10. The average RNA integrity number was uniform across
treatments (Figure 4). RNA was amplified using cDNA synthesis and purification,
followed by in vitro cRNA transcription, then hybridized to Illumina Mouse WG-6
v2.0 cDNA arrays as directed by the manufacturer. The Illumina gene expression
image

files

obtained

from

the

Illumina

iScan

scanner

were

uploaded

to

GenomeStudio (version 2010.3) using the Gene Expression module (v1.8.0). The
quality of the samples was assessed using the Control Summary plots; all samples
were accepted for analysis based on the number of genes detected (Figure 5 A;
acceptable number is 10,000 - 15,000 genes) and the signal-to-noise ratio (Figure
5 B; typically close to 40). No outliers were detected on a dendrogram of all the
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samples (Figure 6). Data were normalized using the Rank Invariant method.
Differentially expressed probes were identified using the Illumina Custom Error
Model with Benjamini and Hochberg False Discovery Rate. The genes considered to
be differentially expressed were uploaded to the Genomatix Software Suite to
determine over-represented Gene Ontology Biological Processes.

Figure 4. RNA Integrity in Hybridized Microarray Samples, as Assessed By the
Bioanalyzer 2100.
A, Total RNA before amplification. Sample identification numbers at the top of the
lanes are: 1:WT; 2:MUT; 3:WT+Rosi; 4:MUT+Rosi. a, b and c denote the
replicate numbers. B, RNA integrity number (RIN) by sample. No differences
between groups were detected by ANOVA.

28

A

29

B

Figure 5. Summary of Quality Control Measurements for Hybridized Microarray
Samples.
A, Total number of detected genes detected on hybridized arrays at the 95%
(blue line) and 99% (red line) confidence level, in each hybridized sample. The
index on the x-axis indicates sample identification: 1-4, replicate a; 5-8, replicate
b; 9-12, replicate c; order is WT, WT+Rosi, MUT, MUT+Rosi for each set of
replicates. B, Signal-to-noise ratio for each sample presented as in panel C.
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Figure 6. Dendrogram of All Hybridized Microarray Samples.

2.12

Bioinformatic PPRE Prediction.

Gene promoters were defined by the Gene2Promoter function of Genomatix
and searched for PPARγ binding sites consistent with the matrices generated by
Lefterova et al. (defined in Genomatix MatInspector as V$PPARG.02) and Nielsen et
al. (V$PPARG.03). All of the gain-of-function promoters and 1000 randomly
selected promoters of the loss-of-function set were scanned for PPREs. The
incidences of PPREs in the promoters of gain-of-function and loss-of-function genes
were compared using Fisher’s exact test. Human-mouse promoter alignments were
done in Rvista 2.0 [93], which was also used to confirm the presence of the
putative PPREs.
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3 In Silico ANALYSIS OF E157D PPARγ STRUCTURE
3.1

E157D Is Not a Tolerated Change in Nuclear Receptor
Sequence Alignment.
To gain a better perspective on the importance of glutamate 157 for PPARγ

function, we analyzed the E157D mutation using SIFT, a program that predicts the
functional impact of protein mutations based on the conservation of the mutated
site in homologous proteins. Because the phenotypic impact of the E157D mutation
in humans is already known in detail, the major goal of this experiment was to
examine glutamate 157 as it relates to other members on the nuclear receptor
superfamily. SIFT generated an alignment of 86 homologous human protein
sequences centered around position 129 of PPARγ1, with a median sequence
conservation score of 3.16, indicating that the prediction was not based on
sequences that are too closely related. The E to D substitution was assigned a score
of 0.00, indicating that this mutation is extremely likely to affect protein function.
Given that the biochemical properties of the wild-type and mutant amino acids are
taken into account in generating the score, the extremely strong score for the
subtle E to D mutation indicates that either the glutamate at position 157 is very
highly conserved across different nuclear receptors, or that steric effects play a
major role in this part of the protein. The first explanation is unlikely considering
our knowledge of the variability of nuclear receptor p-box sequences; in fact, HNF4
is one nuclear receptor which has an aspartate in position 157, although the
remainder of its p-box sequence is also very different from PPARγ. The proximity of
the p-box to the DNA molecule may require very precise steric structure in order to
properly recognize and bind the DNA, and the aspartate in position 157 may not be
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viable for interacting with the DNA molecular without also changing the neighboring
amino acids in the alignment. Clearly, glutamate 157 is an important part of the pbox, and even such a minor change as deletion of one unit of its carbon chain
results in major changes in the protein function.

3.2

E157D Is Not Predicted to Change PPARγ Backbone
Structure.
Having ascertained that glutamate 157 is of crucial functional importance for

PPARγ, we used in silico modeling to predict the effect of the E157D mutation on
PPARγ structure. Figure 7 shows the crystal structure of the PPARγ1-RXRα-PPRE
complex in Swiss-Pdb viewer. Glutamate 129 (equivalent to the glutamate 157 in
PPARγ2) is located at the base of helix 1 of the DNA binding domain, and the side
chain protrudes directly into the major groove of the PPRE 5’ half-site. The
GROMOS energy minimization algorithm within the Swiss-Model software was
applied to both the wild-type PPARγ template, and to its E129D mutated version.
The backbone structure of the protein was not detectably altered by the mutation
(Figure 7 A and B). Notably, mutating the same site to an alanine, glycine or
histidine also did not alter the structure of the backbone, indicating that the
functional importance of this site is not likely to be due to its effect on protein
folding.
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3.3

E157D May Compromise the Hydrogen Bonding Between
PPARγ and the PPRE Molecule.
The close relation of glutamate 157 to the PPRE molecule prompted us to

examine its hydrogen bonding with the DNA and whether it is affected by the
E157D substitution. Figure 7 C shows a magnified view of the helix 1 and the
hydrogen bond that glutamate 129 makes with cytosine base of the guaninecytosine base pair in position three of the 5’ PPRE half-site (AGGTCA A AGGTCA). In
panels D - F of Figure 7, three energy-favorable conformations of the mutated
aspartate side chain are shown, of which only one variation comes within hydrogen
bonding distance of the cytosine base, and this distance is longer (3.30 Å) than the
wild-type hydrogen bond (3.02 Å). The shorter carbon chain of aspartate compared
with glutamate moves the carboxyl group further away from the nitrogen atom on
the cytosine base, weakening or eliminating the hydrogen bond.
An important limitation of this approach is the fact that the topologies of
nucleotides and sugars are not yet supported by the GROMOS algorithm, so the
PPRE structure was not taken into account for energy minimization. Our conclusion
about the mutant protein-DNA relationship is made on the assumption that the
mutated DNA binding helix fits into the major groove in exactly the same spatial
relationship as the wild-type, which is not necessarily true. To confirm our findings
with another in silico approach, we used the Monte Carlo energy minimization
algorithm within the ICM-Pre Mol-Soft program, which includes nucleic acids and
works on a local environment for a defined residue rather than the whole protein.
Using this approach, we detected the hydrogen bond between glutamate 129 and
cytosine 4012, which was lost after mutating the glutamate to aspartate (not

34
shown), with a similar lengthening of the bond distance as we observed using the
GROMOS force fields within the Swiss-Model program.
Another important limitation for in silico structural analysis, which requires a
template with known structure, is that the crystal structure has only been resolved
for the consensus PPRE, so any structural changes induced to the protein by various
DNA sequences are not taken into account in our experiment. Our in-vitro studies
that followed were designed to address the fine differences between various PPRE
sequences in their interaction with the wild-type and mutant PPARγ.
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Figure 7. In Silico Modeling of E157D PPARγ.
DNA binding domain of WT (A) and MUT (B) human PPARγ1 with a transverse
view of helix 1. The ligand-binding domain of PPARγ and the entire RXRα protein,
as well as their respective ligands, were hidden from this view to expose the pbox PPARγ region. E129 of human PPARγ1, shown here, is equivalent to E157 of
PPARγ2. C, Hydrogen bond contact between E157 and the PPRE. D-F, Hydrogen
bond contacts of various orientations of D157 with the PPRE.
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4 E157D PPARγ TRANSCRIPTIONAL ACTIVITY IN
REPORTER ASSAYS
4.1

NIH3T3 Cell Line and the Transient Transfection System.
We selected the NIH3T3 cell line for our transient transfection and, later,

lentiviral infection experiments. This is a mouse fibroblast cell line that does not
express endogenous PPARγ, allowing us to study the activity of the mutant protein
overexpressed transiently or by stable infection, without interference by the
endogenous wild-type protein. NIH3T3 cells are efficiently (30%-50%) transfected
with lipophilic agents, and have been widely used as a host cell line for transient
transfection studies of PPARγ activity using the luciferase reporter gene system.
To examine the effect of the E157D mutation on the transcriptional activity of
PPARγ, we used a luciferase reporter assay in a transiently transfected cell culture
model. The luciferase reporter assay is commonly used to quantify the activity of
transcription factors with well-defined DNA binding motifs [94] [95], to characterize
regulatory

DNA

elements

[96-98],

and

has

been

used

to

measure

the

transcriptional activity of PPARγ on various PPREs [99-102], as well as its
responsiveness to various ligands [103-106]. Our transcription reporter plasmid
contains the firefly luciferase reporter gene under the control of the thymidine
kinase promoter, with each of the PPREs listed in Table 2 inserted directly upstream
of the promoter. Thus, each reporter plasmid is identical except for the 25-basepair PPRE sequence, allowing us to directly examine the influence of the DNA
binding site on the transcriptional activity of PPARγ. When PPARγ is present in the
cell, it binds to the PPRE and enhances the basal level of luciferase transcription,
which is quantified by measuring luciferase activity in a luminescence assay of the

37
cell lysate. Addition of the PPARγ ligand rosiglitazone further increases the
transcriptional activity readout.

Table 2. PPREs from Known PPARγ Target Genes.
The DR1 sequence for each PPRE is shown in bold-face. *, PPRE sequence is in
the non-coding strand of the gene.
Location
Gene

PPRE

rel. to

symbol

symbol

PPRE sequence

TSS

Fabp4

ARE7

CTTACTGGATCAGAGTTCACAGATC

-5360

Fabp4

ARE6

CTCTCTGGGTGAAATGTGCATTTCT

-5263

Slc27a1

FATP

AGAAGAAGGGGAAAGGGCAGGAAGG

-489

LPL*

GGAAGTGGGGCAAAGGGCACAGGAT

Function
Intracellular lipid
metabolism
Intracellular lipid
metabolism
Intracellular lipid
metabolism

Species

Ref.

mouse

[43]

mouse

[53]

mouse

[107]

rat

[108]

human

[109]

mouse

[110]

mouse

[111]

mouse

[49]

rat

[112]

rat

[113]

Lipolysis of
Lpl

-160

circulating
triglycerides

Adipoq

ADN*

GAAGATGGGGCAAAAGTCAAAACCA

-250

Sorbs1

CAP

TGACACAGGCTAAAGGTCATCTGAA

-1090

Adipose derived
hormone
Intracellular signal
transduction
protein
Membrane

Aqp7

AQP7*

TTCTCCAGGGGAGAGGTCAGTAGGG

-93

channel; water
balance

Me1

MEp

CTTTCTGGGTCAAAGTTGATCCCCC

-382

Acox1

ACO*

GGGACCAGGACAAAGGTCACGTTCG

-572

Pck1

PCK2

ACAACTGGGATAAAGGTCTCGCTGC

-998

Pyruvate
metabolism
Fatty acid betaoxidation
Gluconeogenesis
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4.2

E157D PPARγ Transcriptional Activity on Various PPREs.
Transient transfection of NIH3T3 cells with PPARγ1 expression plasmids

resulted in equal protein levels of the wild-type and E157D PPARγ1 (Figure 8 B),
indicating that the mRNA stability, translation dynamics and protein turnover are
not likely to be affected by the mutation. The codon frequency change
corresponding to the E157D mutation is insignificant (0.03 to 0.026 [114]), so it is
unlikely that tRNA availability would affect the rate of the mutant protein synthesis.
PPARγ1 significantly induced luciferase transcription from several wellcharacterized PPREs compared to the empty vector control (Figure 8 A), and
addition of a receptor-saturating concentration of rosiglitazone further enhanced
the transcription activation approximately two-fold, validating our assay system.
The E157D mutant PPARγ1 was also transcriptionally active on many of these
PPREs, and was responsive to ligand activation similarly as the wild-type receptor.
However, the transcriptional activity of E157D PPARγ1 was quantitatively lower on
almost all PPREs we tested. In fact, there was only one construct - the full extended
promoter from the aP2 gene - that was more transcriptionally active in the
presence of the mutant PPARγ than the wild-type. Furthermore, we observed that
the extent of the transcriptional defect conferred by the mutation was not uniform
across all PPRE sequences, but displayed a wide range of behaviors when
normalized to the wild-type level of transcription (Figure 9 A). The E157D mutant
PPARγ1 had wild-type level of transcriptional activity on the ACO PPRE, was mildly
to moderately transcriptionally defective on the ARE6, FATP, ADN and MEp PPREs,
and it was transcriptionally dead (no difference compared with the empty vector
control) on the full promoter from the FATP gene, the LPL, AQP7 and PCK2 PPREs.
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We repeated the experiment with several of the PPREs using PPARγ2 and
found that the E157D mutant PPARγ2 behaves similarly as the mutant PPARγ1
when compared to the respective wild-type protein (Figure 8 C and 9 B). The
mutant γ2 isoform activates gene transcription from the four PPREs we examined,
and is further induced by rosiglitazone. However, the mutation reduces its
transcriptional activity compared with the wild-type PPARγ2, and this reduction is
not the same on all PPREs. As with the γ1 isoform, the effect of the E157D mutation
is greater on the FATP and MEp PPREs than it is on the ACO and ARE6 PPREs. There
appears to be no isoform-specific effect of this mutation. This is not surprising given
our knowledge that the two PPARγ isoforms behave similarly in in vitro studies of
transcriptional activity, and we have not explored any differences between the
isoforms further in this project.
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Figure 8. E157D PPARγ Transcriptional Activity in Luciferase Reporter Assays.
A, PPARγ1 wild-type, E157D or empty vector was transiently transfected into
NIH3T3 cells with indicated reporter plasmids, and cells were treated for 24 with
rosiglitazone (Rosi) or DMSO vehicle (veh). B, Western blot of PPARγ1 expression
in transfected cells. C, PPARγ2 transcriptional activity was measured the same
way as in A. Data are means and standard errors of at least two independent
experiments.
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A

B

Figure 9. Normalized Transcriptional Activity of PPARγ in Luciferase Reporter
Assays.
A, E157D PPARγ1 or B, E157D PPARγ2 transcriptional activity relative to wildtype. Data are means and standard errors of at least three independent
experiments. *, p<0.05 compared to WT on the same PPRE. #, no difference
compared with vector.
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4.3

E157D PPARγ Responds to Ligand Activation and Lacks
Dominant Negative Activity.
We examined two commonly-occurring mechanisms through which the

E157D mutation could potentially decreased the transcriptional activity of PPARγ:
decreased ligand responsiveness and dominant negative activity. We considered it
unlikely

that

this

DNA-binding

domain

mutation

could

reduce

the

ligand

responsiveness of PPARγ, as no such cases have been reported and it is generally
believed that the ligand-binding domains of nuclear receptors act independently of
their DNA-binding domains. Furthermore, it was evident from our data that the
mutant receptor is at least partially activated by saturating concentrations of the
synthetic ligand rosiglitazone. However, a mild decrease in endogenous and
synthetic ligand affinity could account for the overall reduction of transcriptional
activity by the mutant PPARγ. To assess the effect of the E157D mutation on PPARγ
ligand affinity quantitatively, we constructed a rosiglitazone dose response curve of
luciferase transcription by the wild-type and E157D PPARγ1. When the maximum
transcription level is set to 100% for each receptor, the ligand response curves are
sigmoid-shaped as expected and are identical for the wild-type and the mutant on
the FATP PPRE (Figure 10), indicating that the ligand affinity of PPARγ is not
affected by the E157D mutation.
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Figure 10. Rosiglitazone Dose Response Curve.
Wild-type (WT) or E157D (MUT) PPARγ1 was transfected into NIH3T3 cells with
the FATP PPRE-luciferase reporter plasmid and treated for 24 hours with
increasing concentrations of rosiglitazone (Rosi). Data are means of three
experiments, normalized to the maximum transcriptional activity for each
receptor. Best-fit dose response curves were constructed in GraphPad using the
single binding site Michaelis-Menten model.

The potential for any dominant negative activity of the E157D PPARγ was
important to assess. The nuclear receptor transcription activation cycle includes
DNA binding, interaction with coregulators, chromatin remodeling, initiation of
transcription, and release from the promoter with subsequent degradation by the
ubiquitin-proteasome system [10, 115-117]. Such cycling of the receptor on and off
the target gene promoters is needed for fine-tuned regulation of gene transcription
in responses to changes in ligand stimulation. In the condition of continuous
presence of ligand, the release of ubiquitinated PPARγ from the PPRE and binding
by the next PPARγ molecule is required for continued gene transcription [118-120].
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Dominant-negative DNA-binding domain PPARγ mutants have been described [56],
and the direct interaction between glutamate 157 and the DNA binding site raises
the possibility that this mutation may disrupt the release of PPARγ from the PPRE.
In this case, the mutant receptor would bind the PPRE and activate one round of
transcription, but fail to free the binding site for further transcriptional activation,
making the PPRE inactive for prolonged periods of time. Our observations in the
NIH3T3 cell model with ectopic D157D PPARγ overexpression had thus far
supported this possibility. In the heterozygous condition, which is the naturally
occurring state of this mutation, the dominant-negative E157D PPARγ would
prevent the transcriptional activity of the wild-type, leading to the severe metabolic
phenotype. On the other hand, previous in vitro studies involving p-box PPARγ
mutations have not found a significant effect on DNA binding, and the subtlety of
this glutamate-aspartate substitution suggests that a severe disruption in DNA
binding and release may be less likely.
To assess the E157D PPARγ for dominant negative activity, we conducted a
competition experiment in which both the wild-type PPARγ and increasing amount
of the mutant receptor were co-transfected into the same cell in the context of our
established transcription reporter assay. As shown in Figure 11, increasing the
amount of wild-type receptor produced the expected rise in transcription, indicating
that the amounts of transfected plasmid are within the linear portion of the PPARγ
transcription curve. Adding increasing amounts of a known dominant-negative
PPARγ mutant, P467L, produced the expected inhibition of transcription. This
mutant binds DNA, but fails to bind ligands, initiate transcription, and release from
PPRE, effectively blocking the wild-type PPARγ from transcribing on that PPRE.
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When we added increasing amounts of the E157D PPARγ plasmid, however, no such
inhibition of transcription was observed. On the contrary, there was a rise in
transcription that did not reach the levels of the wild-type, consistent with
decreased transcriptional activity of the mutant receptor. So, even though the
mutation is inherited in an autosomal dominant pattern, there is clearly no
dominant negative activity in the biochemical sense.

Figure 11. Competition Assay of PPARγ Transcrpitional Activity.
Wild-type and increasing amounts of indicated competing PPARγ1 receptor were
co-transfected into NIH3T3 cells with no exogenous ligand. Data are means and
standard errors of three independent experiments. *, p<0.05 determined by twoway ANOVA.

Our transcription reporter assays on heterologous promoters containing
various PPREs have revealed that the E157D mutation generally reduces the
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transcriptional activity of PPARγ through a mechanism that does not involve
decreased ligand affinity or dominant negative activity. Furthermore, this reduction
in transcriptional activity is dependent on the PPRE sequence and varies widely in
its effect size compared with the wild-type receptor. These observations were
consistent with our hypothesis that the mutation alters the DNA binding site
selectivity of PPARγ and prompted us to examine the PPRE sequences tested here
for patterns that may predict the behavior of the mutant. The receptor directly
contacts the third nucleotide of the 5’ half-site of the PPRE, one of the most highly
conserved bases in the PPRE, and not surprisingly, all of the PPREs tested here
contained a guanine in that position. We next examined the neighboring bases at
positions two and four. The second base of the PPRE is a very highly conserved
guanine; the fourth is variable and all four bases are represented in our set of
assays, but we found no obvious correlation with the severity of the transcriptional
defect. Clearly, the sequence of the PPRE is important in regulating the
transcriptional activity of the mutant receptor, but we were unable to predict the
identity of the base-pairs within the PPRE that would most strongly influence the
receptor. The three-dimensional shape of the DNA molecule is a complex structure
that is determined by more than just the immediate base-pair sequence [121-123],
so a more rigorous analysis of how the mutant PPARγ interacts with various PPRE
sequences was necessary.
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5 E157D PPARγ BINDS DNA In Vitro
We examined the ability of E157D PPARγ to bind PPREs in vitro using the
electrophoretic mobility shift assay (EMSA). In this assay, synthetic doublestranded biotinylated PPRE molecules (probes) are mixed with nuclear extracts from
cells transfected with PPARγ in a binding reaction, then separated on a native
polyacrylamide gel and blotted onto a positively-charged nylon membrane. The
biotin-labeled probe is then detected using streptavidin, and a slow-traveling
(shifted) band represents a protein-DNA complex, compared with the free probe
which travels faster. Analysis of the relative intensity of the shifted bands also
provides a semi-quantitative assessment of protein affinity for various binding sites.
The EMSA has been used successfully to characterize novel PPREs ([99, 100, 124127] and many more) and to determine the relative PPRE affinity of site-directed pbox PPARγ mutants [22].
We first established the validity of the EMSA using the consensus PPRE as
probe. The binding reaction with nuclear extract containing either wild-type or
E157D PPARγ produced a shifted band compared to the control nuclear extract,
which was transfected with the empty vector (Figure 12). The shifted bands were of
similar intensity, and the specificity of PPARγ binding to the probe was confirmed
with a 200-fold molar excess of unlabeled PPRE, which eliminated the shifted band,
and with a super-shifted band produced by adding the M2 Flag antibody, but not
the IgG control. The ADN PPRE also bound the mutant receptor as strongly as the
wild-type, a surprising finding considering that the mutant PPARγ was much weaker
than the wild-type at transcribing from this same PPRE in our luciferase reporter
assay (Figures 8 and 9).
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Figure 12. Validation of the Gel-Shift Assay.
Nuclear lysates from CHO cells transfected with the indicated plasmids were
incubated in a binding reaction with the consensus (top panel) or ADN (bottom
panel) PPRE, plus competitor or antibody, as indicated. Shifted and supershifted
bands represent the PPARγ1-RXRα-PPRE complex.

It was possible that permissive EMSA binding conditions or saturating
amounts of PPARγ in the binding reaction prevented us from detecting a difference
in the binding affinity induced by the E157D mutation. We characterized the DNA
binding activity of the mutant in more detail by testing increasing amounts on the
nuclear extract and generated a binding curve using the relative intensities of the
shifted bands (Figures 13 and 14). To our surprise, the E157D PPARγ bound all of
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the PPREs that we tested with equal or slightly stronger affinity as the wild-type
receptor.

Figure 13. Gel-Shift Assay Blots.
A, Western blot of PPARγ expression in NIH3T3 nuclear extracts used for gel-shift
assays. B, Representative gel-shift blot with the ADN PPRE probe and increasing
amounts of indicated nuclear extracts. C, Shifted bands from gel-shift blots with
the indicated PPRE as probe.
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Figure 14. Gel-Shift Binding Curves.
Shifted band densitometry was performed with ImageJ, and best-fit lines
constructed in GraphPad using either linear or exponential models.
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These results contradict our original hypothesis that the E157D mutation
disrupts the binding site selectivity of PPARγ: at least in the in-vitro binding
conditions, the PPRE selectivity of PPARγ is unaffected by the mutation. However,
our

transcriptional

activity

assays

showed

that

the

mutant

receptor

is

transcriptionally defective on most of these same PPREs. The E157D mutation
appears to act by a more complex mechanism than a change in the DNA binding
affinity of the receptor. A post-DNA binding event in the transcriptional activation
cascade is disrupted, leading to decreased transcriptional activity with no dominantnegative of loss-of-function effect on its ability to bind DNA. Furthermore, the
sequence of the PPRE is important in determining the extent of transcriptional
defect of the mutant receptor, as discussed above. Considering the position of
glutamate 157 in the major groove on the PPRE, it becomes clear that the PPREPPARγ interaction plays an important role in regulating PPARγ transcriptional
activity, beyond just anchoring the receptor on the DNA.
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6 E157D PPARγ HAS REDUCED TRANSCRIPTIONAL
ACTIVITY ON ENDOGENOUS PROMOTERS
6.1

Generation of Stable PPARγ-Expressing Fibroblasts.
Our experiments thus far have shown that E157D PPARγ binds PPREs in

vitro, but fails to induce transcription from most PPREs in the context of a
heterologous promoter. Transcriptional activity on native chromatin may be
regulated by additional factors including chromatin folding, methylation marks, and
cis-acting regulatory proteins bound to nearby sites. In addition, overexpressed
protein activity in our transient transfection system may be altered compared to
normal levels of expression. To investigate the transcriptional activity of E157D
PPARγ in a more natural setting, we used the lentiviral gene delivery system to
generate NIH3T3 fibroblasts expressing equal, physiologically-relevant levels of the
wild-type or E157D PPARγ.
The lentiviral expression plasmid recombines with endogenous DNA at
random locations within the chromatin, with on average two insertions of the gene
in each infected cell [128]. NIH3T3 cells are readily transduced with lentivirus
[128], and have been used to establish PPARγ-expressing cell lines to study the
transcriptional activity differences between the different PPAR isoforms [90]. The
PPARγ protein expressed from a lentiviral insert in this system induces the
expression of many known PPARγ target genes. The pLenti6.3 vector used in our
experiments contains the CMV promoter driving the expression of the transgene
and, in the same transcript, the blasticidin resistance selection marker, translated
from in internal ribosome binding site. In a kill-curve experiment, 2 μg/mL - 10
μg/mL blasticidin concentrations were sufficient to kill non-infected NIH3T3 cells, so
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we used the lowest effective 2 μg/mL concentration of blasticidin for all subsequent
selection and maintenance of virus-infected cells. Cell death was not significantly
induced in the lentivirus-infected wells, while all non-infected control cells were
dead after seven days of selection, indicating that infection efficiency was high in
our experiments. The infected cells were maintained for an additional week for a
total of two weeks selection period before we started the gene expression
experiments. We termed the established transgenic cell lines NPγ1WT (NIH3T3derived PPARγ1 Wild-Type expressing cells), NPγ1E157D (expressing the γ1 isoform
of the mutant receptor), NPγ2WT, NPγ2E157D (expressing the corresponding γ2
forms of PPARγ, and NLacZ (infected with the control Lac-Z coding vector).
Lentivirus-delivered PPARγ was expressed at the mRNA and protein level
(Figure 15). Compared with the mouse differentiated 3T3-L1 adipocyte cell line,
which expresses high levels of PPARγ, our lentivirus-infected cells expressed similar
levels of PPARγ mRNA, but slightly reduced levels of the protein. Any regulatory
elements of the native PPARγ transcript are absent from the lentiviral PPARγ
expression vector, which contains only the cDNA and the Kozak sequence, so
translation from this minimal transcript is likely less efficient than the native mRNA
species, resulting in reduced protein levels. Nevertheless, PPARγ protein expression
in our stable cell lines is likely comparable to the levels of its expression in nonadipose tissues. The control cell line was infected with the lentiviral vector for LacZ,
and showed no detectable expression of the endogenous PPARγ gene in these cells.
Lastly, we discovered that PPARγ protein expression decreased slowly over time
with passaging the transduced cells. Loss of transgene expression in virus-infected
“stable” cell lines is not uncommon after several passages, due to either expression
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from non-integrated viral particles, silencing of the transgene, or selection for lowexpressing cells if the transgene causes slower growth [129]. Therefore, all
experiments were carried out using cell lines of equal age and passage number.

Figure 15. Transgene Expression in Stable Lentivirus-Infected Cell Lines.
A, mRNA and B, protein expression of PPARγ in the indicated lentivirus-infected
cell lines or in differentiated 3T3-L1 adipocytes were measured in by rtPCR and
western blot.

6.2

E157D PPARγ is Activated by Rosiglitazone on
Endogenous Promoters.
To assess the transcriptional activity of E157D PPARγ on native gene

promoters, we first confirmed that endogenous PPARγ target genes are induced by
PPARγ in the lentivirus-infected expression system. We measured the expression of
several genes reported to be induced by PPARγ in similar experimental conditions
[90] using end-point reverse transcriptase-PCR after treating the cells for 24 hours
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with 20 μM rosiglitazone. Four of the transcripts (fatty acid binding protein aP2,
adiponectin, perilipin 4 and fatty acid transporter CD36) were upregulated in wildtype PPARγ2-expressing cells (Figure 16 A) and further induced by rosiglitazone.
The adiponectin mRNA was upregulated after 3 hours of rosiglitazone treatment
and reached maximal induction at 24 hours (Figure 16 B), indicating that the
transcriptional dynamics of the lentivirus-expressed PPARγ are normal. Gene
transcription induced by the E157D PPARγ2 failed to reach the levels of wild-type
PPARγ2-induced transcription (Figure 16 A), suggesting that the mutant receptor is
transcriptionally defective on endogenous promoters, as is the case on heterologous
promoters.

Figure 16. Rosiglitazone Induces Transcription of Endogenous PPARγ Target
Genes In Wild-Type and E157D NPγ2 Cells.
A, Expression of endogenous genes was measured by rtPCR in the indicated cells
treated for 24 hours with 20 µM rosiglitazone (+ Rosi) or vehicle (- Rosi). B,
Gene expression in NPγ2WT cells after exposure to 20 µM rosiglitazone for the
indicated durations.

56

Importantly, no adipogenic changes or evidence of lipid storage were
observed in the transgenic cell lines after 24 hours of rosiglitazone treatment.
NIH3T3 cells are relatively resistant to adipogenic differentiation, requiring
additional stimulation with hormones, and longer than 24 hrs of rosiglitazone.
Endogenous ligands alone did not induce adipogenesis in either wild-type or E157D
PPARγ-expressing cells.

6.3

E157D PPARγ Activates Transcription of Native PPARγ
Target Genes but Fails to Reach Maximal Induction.
End-point PCR can lack the sensitivity needed to detect differences in mRNA

abundance, so to better characterize the effect of the E157D mutation on PPARγ
transcriptional activity on various endogenous PPREs, we measured the mRNA
levels of PPARγ target genes using quantitative PCR. We found that on five PPARγresponsive promoters, rosiglitazone-activated E157D PPARγ induced transcription
but failed to reach the level induced by the wild-type PPARγ. This was true of both
the PPARγ1 and PPARγ2 isoforms of the receptor (Figure 17). Furthermore,
similarly as on the heterologous promoter constructs, the extent of transcriptional
defect conferred by the mutation was not uniform on all endogenous promoters. For
instance, induction of the CD36 gene transcription was severely reduced by the
E157D mutation (hundreds of fold), while activity on the perilipin and aP2 genes
was only mildly reduced (less than ten-fold), and the adiponectin gene was induced
about thirty-fold weaker by the mutant than the wild-type PPARγ. These data
support our working model in which the DNA binding site sequence regulates the
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transcriptional activity of PPARγ, and plays a role in determining how strongly the
transcriptional activity of the receptor is affected by this PPRE-interacting mutation.

Figure 17. E157D PPARγ Transcriptional Activity on Endogenous PPARγ Target
Promoters.
Expression of indicated genes was measured by qPCR and normalized to PPIA.
Means and standard errors of three or four independent experiments are shown.
*, p<0.05 determined by ANOVA with post-hoc Bonferroni tests.
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6.4

E157D PPARγ binds endogenous PPREs.
We have shown that cells with stable E157D PPARγ expression have reduced

levels of several known PPARγ target transcripts after rosiglitazone induction
compared with cells expressing the wild-type receptor, and that this general pattern
is not the same for each transcript. These findings very closely mimic our data from
the transiently transfected transcription reporter system. To confirm that altered
DNA binding affinity does not mediate the changes in induction of endogenous
PPARγ genes by the mutant receptor, we measured the E157D PPARγ occupancy on
the promoters of two of the genes for which the location of the PPREs in known.
In fibroblasts transfected with either wild-type or E157D biotinylated PPARγ1,
streptavidin precipitation resulted in similar enrichment of the PPRE-containing
regions compared with the empty vector-transfected contol, indicating that the
mutation does not affect the binding affinity of PPARγ on native promoters. This
was true on both aP2 and adiponectin gene promoters (Figure 18 B), while a control
genomic region containing no known PPREs was not enriched with either protein,
confirming specific pull-down. By contrast, the expression profiles of these two
genes were dramatically different upon treatment of NPγ1 cells with rosiglitazone
(Figure 18 A, same data as in Figure 17). While the E157D mutation did not change
the aP2 gene induction by PPARγ, it reduced adiponectin gene induction by almost
thirty-fold compared with the wild-type receptor.
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Figure 18. E157D PPARγ occupancy on endogenous PPARγ target promoters.
A, Gene expression in NPγ1 cells was measured by qPCR, data from Figure 17. B,
Chromatin immunoprecipitation (IP) assays of transfected biotinylated PPARγ
(empty vector control, wild-type or E157D) on the promoter regions of genes
shown in panel A.
These findings are fully consistent with our initial in-vitro studies and confirm
an unusual mechanistic aspect of the E157D PPARγ mutation, which disrupts the
transcriptional activity of the receptor in a PPRE sequence-specific manner, but has
no effect on DNA binding affinity. This intrinsic mechanism is evident both on
endogenous promoters and in a transiently-transfected system.
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7 GLOBAL CHANGES IN E157D PPARγ TRANSCRIPTIONAL
ACTIVITY
Our data thus far have demonstrated that E157D PPARγ binds PPREs in vitro
equally well as the wild-type, despite the DNA-binding surface mutation, and
activates transcription from PPREs in the context of heterologous plasmid and
native-chromatin promoters. Transcription induction from most of the classic, welldefined PPREs that we studied was reduced by the E157D mutation, with some
PPREs more strongly defective than others in directing E157D PPARγ transcriptional
activity. This apparent spectrum of defectiveness, from no effect of the mutation to
mildly defective, to strongly defective and transcriptionally dead, led us to
investigate whether there are genes that are induced by E157D PPARγ above the
levels of the wild-type PPARγ-mediated transcription. In the context of the severe
diabetic phenotype of E157D PPARγ carriers, we were interested in any such genes
as potential candidate genes in the pathogenesis of insulin resistance - something
that is not currently well understood. From the molecular viewpoint, we were
interested in the mechanistic aspects of transcriptional activation by E157D PPARγ
as directed by the PPRE sequence.

7.1

E157D PPARγ Regulates a Smaller Set of Genes than the
Wild-Type Receptor.
To characterize the global extent of E157D PPARγ transcriptional activity, we

determined the total set of genes regulated by E157D PPARγ in the stable PPARγ
expressing fibroblasts using mRNA profiling. Total RNA was isolated from NPγ2
wild-type or E157D cells expressing equal amounts of PPARγ (Figure 18) in three
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independent experiments after 24 hours of activation with rosiglitazone or DMSO
vehicle. Amplified cRNA representing the total transcriptome of the cells was
hybridized to mouse cDNA arrays for detection of differentially expressed genes
from DMSO- versus rosiglitazone-treated cells. We defined the set of genes that
were significantly upregulated by rosiglitazone treatment as PPARγ target genes for
each of the two cell lines. Wild-type PPARγ induced the expression of 1631 genes,
597 of them by 1.5-fold or greater (Table 3), consistent with previously described
transgenic cell culture models [90]; by contrast, the E157D mutant induced 287
genes, only 95 of them over 1.5-fold.
In addition to induction of gene transcription, activation of PPARγ leads to
inhibition of certain genes through incompletely understood mechanisms involving
either direct activity of PPARγ on the gene promoters or upregulation of genes
encoding transcriptional inhibitors. In the currently accepted model of direct
inhibition of transcription, ligand binding induces sumoylation of the ligand-binding
domain of PPARγ, which targets it to corepressors on the promoters of
inflammatory genes and prevent the disassembly of the repression complex upon
inflammatory stimulation [130-135]. In our transgenic cell model, activation of
PPARγ with rosiglitazone resulted in decreased transcription of 1053 probes (66 of
those by more than 50%). The E157D mutant downregulated a significantly smaller
set of genes (297; only 8 of those by more than 50%). Whether these genes are
regulated through direct or indirect mechanisms, the mutant receptor has
decreased inhibitory activity as well as decreased stimulation of gene transcription.
These data confirm that, similarly as we observed on a small set of well-known
PPARγ target genes, the E157D PPARγ is largely transcriptionally defective on a
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global scale: it regulates the transcription of a much smaller set of genes than the
wild-type receptor.

Figure 19. Lentiviral PPARγ Expression in Hybridized Samples.
Protein expression was measured by western blot in NPγ2 WT and E157D cells.

Table 3. Summary of Microarray Analysis of Gene Expression.
The numbers of genes with positive signal from one or more array probe are
listed

NPγ2 WT

NPγ2 E157D

Rosi-induced genes

1631

287

Rosi-induced genes, FC>1.5

597

95

Rosi-downregulated genes

1053

297

Rosi-donregulated genes, FC<0.5

66

8

7.2

E157D PPARγ Exhibits Novel Transcriptional Properties.
In order to better understand the global effect of the E157D mutation on the

transcriptional activity of PPARγ, we analyzed the target genes of wild-type and
E157D PPARγ as defined by rosiglitazone induction in our NPγ2 cells. The mutant
receptor failed to activate transcription of 90% of the wild-type PPARγ target genes
(Figure 19). The majority of the E157D PPARγ target genes are also wild-type
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targets, and the mutant receptor has reduced transcriptional activity on most
(73%) of these genes. We refer to these as the “loss-of-function” genes, indicating
the effect of the E157D mutation. The remainder (27%, or 15 genes) of shared
wild-type and E157D PPARγ target genes are induced similarly by both receptors.
In addition, a significant portion (38%), of E157D PPARγ target genes are not wildtype PPARγ targets, although this is a small number relative to the total number of
wild-type PPARγ target genes (34 versus 528 genes). We refer to these 34 genes as
the “gain-of-function” genes. Genes repressed by PPARγ followed a very similar
pattern, but amounted to roughly a tenth of the total number of genes induced by
PPARγ. Here also the mutant receptor was inactive on the vast majority of the
genes down-regulated by the wild-type PPARγ, while one gene was repressed by
mutant receptor only.
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Figure 20. Summary of Wild-Type and E157D PPARγ Target Genes.
Each segment of the Venn diagram represents the number of genes in that
category after the fold-change cut-off. Representative enriched biological
processes for each segment of the diagram are listed. Note, the numbers of
genes in each section is slightly lower than the numbers listed in Table 3 because
only the annotated genes were entered into the analysis of biological processes.

To investigate the functional implications of the changes in transcriptional
activity of the E157D PPARγ, we used the Genomatix software to identify biological
processes that are enriched in the various gene categories with respect to the effect
of the mutation. Surprisingly, the gain-of-function genes comprise an entirely
functionally distinct set of genes than the wild-type PPARγ targets. Consistent with
previous reports and known PPARγ physiology [19, 136-139], the wild-type PPARγ
target genes fell into the expected categories of adipogenesis, lipid storage,
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mitochondrial function and other categories (Table 4). On the other hand, the lossof-function genes were enriched for embryonic development, and specifically
neurogenic and angiogenic developmental factors (Table 5). Importantly, the
enrichment terms of the gain-of-function and the loss-of-function gene sets were
completely

non-overlapping.

Such

a

striking

segregation

of

gene ontology

categories with respect to E157D PPARγ transcriptional activity implies that there is
a significant functional meaning in the gain of function conferred by the mutation.

Table 4. Enriched Biological Processes in the E157D PPARγ Loss-of-Function Gene
Set.
Metabolic categories are highlighted in blue.
# Genes
GO-Term

GO-Term id

P-value

cellular process

GO:0009987 5.15E-13 76

# Genes

# Genes

(observed) (expected) (total)
40.098

11371

List of observed genes
Hspd1, Rreb1, Cat, Ddit3, Egln3, Itgad, Col18a1, Adipoq,
Nus1, Trib3, Gpcpd1, Aco2, Mfsd7a, Taldo1, S100a13,
Atpaf2, Cebpg, etc.

metabolic process

GO:0008152 3.92E-14 61

25.055

7105

Hspd1, Rreb1, Pnpla8, Cat, Ddit3, Egln3, Cyb5r1, Adipoq,
Trib3, Gpcpd1, Aco2, Taldo1, Cebpg, Dgat2, Tpsab1, Pdhb,
Cycs, Tob1, etc.

cellular metabolic

GO:0044237 1.23E-12 54

21.437

6079

process

Hspd1, Rreb1, Cat, Ddit3, Adipoq, Trib3, Gpcpd1, Aco2,
Taldo1, Cebpg, Dgat2, Pdhb, Cycs, Tob1, Aldh1a7, Esrra,
Agpat2, Cs, Ahcyl2, etc.

primary metabolic

GO:0044238 2.08E-10 51

21.966

6229

process

Hspd1, Rreb1, Pnpla8, Cat, Ddit3, Cyb5r1, Adipoq, Trib3,
Gpcpd1, Taldo1, Cebpg, Dgat2, Tpsab1, Pdhb, Tob1,
Aldh1a7, Esrra, etc.

small molecule

GO:0044281 1.54E-18 34

5.455

1547

metabolic process

Cat, Cyb5r1, Adipoq, Trib3, Gpcpd1, Aco2, Taldo1, Dgat2,
Pdhb, Aldh1a7, Cs, Ahcyl2, Aldoa, Fads3, Pcx, Prkar2b,
Fitm2, Acadvl, etc.

biosynthetic process

GO:0009058 1.35E-04 26

12.236

3470

Rreb1, Cat, Ddit3, Cyb5r1, Adipoq, Trib3, Cebpg, Dgat2,
Pdhb, Tob1, Esrra, Agpat2, Fads3, Pcx, Fitm2, S100a1,
Acadvl, Mrpl12, etc.

cellular biosynthetic
process

GO:0044249 2.22E-04 25

11.891

3372

Rreb1, Cat, Ddit3, Adipoq, Trib3, Cebpg, Dgat2, Pdhb,
Tob1, Esrra, Agpat2, Fads3, Pcx, Fitm2, S100a1, Acadvl,
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Mrpl12, Agpat9, etc.
lipid metabolic process GO:0006629 1.25E-16 24

2.648

751

Pnpla8, Cat, Cyb5r1, Adipoq, Trib3, Gpcpd1, Dgat2,
Aldh1a7, Agpat2, Fads3, Pcx, Prkar2b, Fitm2, Acadvl,
Acot2, Crat, Pnpla2, etc.

response to stimulus

GO:0050896 3.40E-05 23

9.250

2623

Hspd1, Cat, Ddit3, Egln3, Adipoq, Trib3, Cebpg, Cycs,
Chac1, Mpp1, Cfd, Prkar2b, Acot2, Gadd45g, Aplp2, Itpr1,
Acsl1, Vegfa, Acadm, etc.

localization

GO:0051179 5.53E-04 22

10.431

2958

Col18a1, Adipoq, Trib3, Mfsd7a, S100a13, Slc5a6, Tob1,
Mpp1, Slc25a10, Fads3, Tfrc, Fitm2, Slc25a1, Crat, Pnpla2,
Itpr1, Dgat1, etc.

catabolic process

GO:0009056 2.13E-11 21

3.417

969

Pnpla8, Cat, Adipoq, Trib3, Aco2, Taldo1, Pdhb, Cs, Aldoa,
Rnf11, Acadvl, Acot2, Arl4a, Pnpla2, Por, Acsl1, Bckdhb,
Cbr3, Lpl, Acadm, etc.

cellular lipid metabolic GO:0044255 2.19E-14 19

1.820

516

process

Cat, Adipoq, Trib3, Dgat2, Aldh1a7, Agpat2, Fads3,
Prkar2b, Fitm2, Acadvl, Acot2, Crat, Pnpla2, Agpat9, Dgat1,
Acsl1, Lpl, Acadm, etc.

regulation of

GO:0019222 6.18E-03 19

10.290

2918

metabolic process

Rreb1, Cat, Ddit3, Adipoq, Trib3, Cebpg, Tob1, Esrra,
Prkar2b, Fitm2, S100a1, Acadvl, Gadd45g, Aplp2, Pnpla2,
Por, Vegfa, Acadm, etc.

developmental

GO:0032502 7.90E-03 19

10.533

2987

process

Col18a1, Adipoq, Nus1, Trib3, S100a13, Cebpg, Tob1,
Esrra, Fgfrl1, Prkar2b, Gadd45g, Aplp2, Arl4a, Itpr1, Dmkn,
Pex11a, Vegfa, Lpl, etc.

regulation of cellular

GO:0031323 7.19E-03 18

9.676

2744

metabolic process

Rreb1, Cat, Ddit3, Adipoq, Trib3, Cebpg, Tob1, Esrra,
Prkar2b, Fitm2, S100a1, Acadvl, Gadd45g, Aplp2, Pnpla2,
Vegfa, Acadm, Mknk2

transport

GO:0006810 7.87E-03 17

9.010

2555

Adipoq, Trib3, Mfsd7a, S100a13, Slc5a6, Tob1, Slc25a10,
Fads3, Tfrc, Slc25a1, Crat, Itpr1, Dgat1, Acsl1, Pex16, Cyc1,
Etfdh

establishment of

GO:0051234 8.45E-03 17

9.077

2574

localization

Adipoq, Trib3, Mfsd7a, S100a13, Slc5a6, Tob1, Slc25a10,
Fads3, Tfrc, Slc25a1, Crat, Itpr1, Dgat1, Acsl1, Pex16, Cyc1,
Etfdh

regulation of primary GO:0080090 9.82E-03 17

9.221

2615

metabolic process

Rreb1, Cat, Ddit3, Adipoq, Trib3, Cebpg, Tob1, Esrra,
Prkar2b, Fitm2, S100a1, Acadvl, Pnpla2, Por, Vegfa,
Acadm, Mknk2

cellular ketone

GO:0042180 1.32E-10 16

1.978

561

metabolic process
cellular catabolic

Prkar2b, Acadvl, Acot2, Crat, Acsl1, Bckdhb, Cbr3, Acadm
GO:0044248 9.50E-09 16

2.666

756

process

Cat, Adipoq, Trib3, Aco2, Cs, Rnf11, Acadvl, Acot2, Arl4a,
Pnpla2, Por, Acsl1, Bckdhb, Cbr3, Lpl, Acadm

response to chemical GO:0042221 1.60E-06 16

3.897

1105

stimulus
oxoacid metabolic

Adipoq, Trib3, Aco2, Pdhb, Aldh1a7, Cs, Fads3, Pcx,

Hspd1, Cat, Ddit3, Egln3, Adipoq, Trib3, Cycs, Chac1,
Mpp1, Acot2, Itpr1, Acsl1, Vegfa, Cyc1, Etfdh, Mgst1

GO:0043436 9.00E-10 15

1.929

547

Adipoq, Trib3, Aco2, Pdhb, Aldh1a7, Cs, Fads3, Pcx,
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process
carboxylic acid

Prkar2b, Acadvl, Acot2, Crat, Acsl1, Bckdhb, Acadm
GO:0019752 9.00E-10 15

1.929

547

metabolic process

Prkar2b, Acadvl, Acot2, Crat, Acsl1, Bckdhb, Acadm

organic acid metabolic GO:0006082 9.23E-10 15

1.932

548

process

Adipoq, Trib3, Aco2, Pdhb, Aldh1a7, Cs, Fads3, Pcx,
Prkar2b, Acadvl, Acot2, Crat, Acsl1, Bckdhb, Acadm

positive regulation of GO:0048518 2.06E-03 15

6.517

1848

biological process

Hspd1, Cat, Ddit3, Col18a1, Adipoq, Trib3, S100a13,
Cebpg, Cycs, Esrra, Cfd, Fitm2, Pnpla2, Vegfa, Lpl

cellular developmental GO:0048869 2.50E-03 15

6.651

1886

process
cellular component

Adipoq, Trib3, Aco2, Pdhb, Aldh1a7, Cs, Fads3, Pcx,

Col18a1, Adipoq, Nus1, Trib3, S100a13, Cebpg, Tob1,
Esrra, Gadd45g, Arl4a, Dmkn, Pex11a, Vegfa, Lpl, Acadm

GO:0016043 8.67E-03 15

7.617

2160

organization

Col18a1, Adipoq, S100a13, Atpaf2, Cebpg, Aldh1a7, Tfrc,
Fitm2, Pex19, Aplp2, Hist1h2bh, Pex11a, Hist1h2bk, Pex16,
Acadm

alcohol metabolic

GO:0006066 2.10E-10 14

1.449

411

process
oxidation reduction

Cat, Cyb5r1, Adipoq, Gpcpd1, Taldo1, Dgat2, Pdhb, Aldoa,
Pcx, Acadvl, Pgm2, Por, Pmm1, Acadm

GO:0055114 4.88E-08 14

2.225

631

Cat, Egln3, Cyb5r1, Pdhb, Cycs, Aldh1a7, Fads3, Acadvl,
Por, Bckdhb, Cbr3, Acadm, Cyc1, Etfdh

response to stress

GO:0006950 2.63E-04 14

4.736

1343

Hspd1, Cat, Ddit3, Egln3, Cebpg, Cycs, Chac1, Cfd, Acot2,
Itpr1, Vegfa, Acadm, Etfdh, Mknk2

cell differentiation

GO:0030154 4.38E-03 14

6.365

1805

Col18a1, Adipoq, Nus1, Trib3, Cebpg, Tob1, Esrra,
Gadd45g, Arl4a, Dmkn, Pex11a, Vegfa, Lpl, Acadm

regulation of biological GO:0065008 1.91E-03 13

5.163

1464

quality

Acadvl, Aplp2, Pnpla2, Itpr1, Dgat1, Vegfa

positive regulation of GO:0048522 5.25E-03 13

5.811

1648

cellular process
monocarboxylic acid

GO:0032787 1.81E-09 12

1.146

325

GO:0008610 2.18E-08 11

1.146

325

Cyb5r1, Trib3, Dgat2, Agpat2, Fads3, Pcx, Fitm2, Acadvl,
Agpat9, Dgat1, Lpl

cellular carbohydrate GO:0044262 4.52E-08 11

1.231

349

metabolic process

Adipoq, Gpcpd1, Taldo1, Dgat2, Pdhb, Cs, Aldoa, Pcx,
Pgm2, Pmm1, Acadm

GO:0005975 6.80E-07 11

1.615

458

metabolic process
generation of

Adipoq, Trib3, Pdhb, Aldh1a7, Fads3, Pcx, Prkar2b, Acadvl,
Acot2, Crat, Acsl1, Acadm

process

carbohydrate

Hspd1, Cat, Ddit3, Col18a1, Adipoq, Trib3, S100a13,
Cebpg, Cycs, Esrra, Pnpla2, Vegfa, Lpl

metabolic process
lipid biosynthetic

Ddit3, Adipoq, S100a13, Cebpg, Aldh1a7, Tfrc, Fitm2,

Adipoq, Gpcpd1, Taldo1, Dgat2, Pdhb, Cs, Aldoa, Pcx,
Pgm2, Pmm1, Acadm

GO:0006091 4.11E-08 10

0.949

269

precursor metabolites

Cat, Aco2, Pdhb, Cycs, Cs, Aldoa, Fads3, Acadm, Cyc1,
Etfdh

and energy
small molecule

GO:0044282 5.22E-06 10

1.615

458

catabolic process
apoptosis

Adipoq, Taldo1, Pdhb, Aldoa, Acadvl, Acot2, Arl4a, Bckdhb,
Cbr3, Acadm

GO:0006915 1.91E-03 10

3.343

948

Hspd1, Ddit3, Egln3, Col18a1, Trib3, Cebpg, Cycs, Chac1,
Gadd45g, Vegfa

programmed cell
death

GO:0012501 2.10E-03 10

3.385

960

Hspd1, Ddit3, Egln3, Col18a1, Trib3, Cebpg, Cycs, Chac1,
Gadd45g, Vegfa

68
cell death

GO:0008219 2.92E-03 10

3.544

1005

Hspd1, Ddit3, Egln3, Col18a1, Trib3, Cebpg, Cycs, Chac1,
Gadd45g, Vegfa

death

GO:0016265 3.09E-03 10

3.572

1013

Hspd1, Ddit3, Egln3, Col18a1, Trib3, Cebpg, Cycs, Chac1,
Gadd45g, Vegfa

Table 5. Enriched Biological Processes in the E157D PPARγ Gain-of-Function Gene
Set.
Developmental categories are highlighted in green; vasculogenesis in red.
# Genes
GO-Term

GO-Term ID

P-value

cellular process

GO:0009987 1.01E-04 14

# Genes

# Genes

(observed) (expected) (total)
6.3

11371

List of observed genes
Cck, Irx5, Kank3, Vav3, Acsbg1, Hvcn1,
Sema5a, Mtap2, Sncg, Klf5, Ramp2,
Sepp1, Dpt, Net1

regulation of cellular process

GO:0050794 9.10E-06 12

3.5

6345

Cck, Irx5, Kank3, Vav3, Hvcn1, Sema5a,
Mtap2, Sncg, Klf5, Ramp2, Dpt, Net1

regulation of biological process

GO:0050789 1.53E-05 12

3.7

6654

Cck, Irx5, Kank3, Vav3, Hvcn1, Sema5a,
Mtap2, Sncg, Klf5, Ramp2, Dpt, Net1

biological regulation

GO:0065007 3.05E-05 12

3.9

7087

Cck, Irx5, Kank3, Vav3, Hvcn1, Sema5a,
Mtap2, Sncg, Klf5, Ramp2, Dpt, Net1

multicellular organismal process

GO:0032501 2.01E-03 8

2.6

4775

Cck, Irx5, Vav3, Sema5a, Mtap2, Sncg,
Klf5, Sepp1

cellular component organization

GO:0016043 8.03E-05 7

1.2

2160

Cck, Kank3, Vav3, Sema5a, Mtap2, Klf5,
Dpt

system development

GO:0048731 1.09E-04 7

1.3

2267

Cck, Irx5, Vav3, Sema5a, Mtap2, Klf5,
Sepp1

anatomical structure development

GO:0048856 1.68E-04 7

1.3

2426

Cck, Irx5, Vav3, Sema5a, Mtap2, Klf5,
Sepp1

multicellular organismal

GO:0007275 3.66E-04 7

1.5

2749

development
developmental process

Cck, Irx5, Vav3, Sema5a, Mtap2, Klf5,
Sepp1

GO:0032502 6.11E-04 7

1.7

2987

Cck, Irx5, Vav3, Sema5a, Mtap2, Klf5,
Sepp1

response to stimulus

GO:0050896 1.99E-03 6

1.5

2623

Cck, Irx5, Acsbg1, Hvcn1, Sncg, Sepp1

cell projection organization

GO:0030030 4.87E-06 5

0.3

485

Cck, Vav3, Sema5a, Mtap2, Klf5

nervous system development

GO:0007399 1.65E-04 5

0.6

1013

Cck, Irx5, Sema5a, Mtap2, Sepp1
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anatomical structure morphogenesis GO:0009653 4.99E-04 5

0.7

1286

Cck, Irx5, Vav3, Sema5a, Klf5

organ development

GO:0048513 2.19E-03 5

1.0

1786

Irx5, Vav3, Sema5a, Klf5, Sepp1

neuron development

GO:0048666 8.54E-05 4

0.2

443

Cck, Irx5, Sema5a, Mtap2

neuron differentiation

GO:0030182 2.34E-04 4

0.3

576

Cck, Irx5, Sema5a, Mtap2

generation of neurons

GO:0048699 3.41E-04 4

0.4

636

Cck, Irx5, Sema5a, Mtap2

cellular component assembly

GO:0022607 3.56E-04 4

0.4

643

Cck, Kank3, Vav3, Klf5

neurogenesis

GO:0022008 4.33E-04 4

0.4

677

Cck, Irx5, Sema5a, Mtap2

cellular component biogenesis

GO:0044085 6.11E-04 4

0.4

742

Cck, Kank3, Vav3, Klf5

cell development

GO:0048468 1.10E-03 4

0.5

868

Cck, Irx5, Sema5a, Mtap2

organelle organization

GO:0006996 2.73E-03 4

0.6

1112

Cck, Kank3, Vav3, Mtap2

negative regulation of biological

GO:0048519 9.91E-03 4

0.9

1599

Cck, Kank3, Mtap2, Dpt

angiogenesis

GO:0001525 1.58E-04 3

0.1

195

Vav3, Sema5a, Klf5

blood vessel morphogenesis

GO:0048514 3.77E-04 3

0.1

262

Vav3, Sema5a, Klf5

blood vessel development

GO:0001568 5.98E-04 3

0.2

307

Vav3, Sema5a, Klf5

vasculature development

GO:0001944 6.39E-04 3

0.2

314

Vav3, Sema5a, Klf5

regulation of system process

GO:0044057 7.00E-04 3

0.2

324

Cck, Irx5, Sncg

neuron projection development

GO:0031175 1.00E-03 3

0.2

367

Cck, Sema5a, Mtap2

regulation of cellular component

GO:0051128 1.61E-03 3

0.2

433

Cck, Kank3, Mtap2

GO:0048646 1.81E-03 3

0.2

451

Vav3, Sema5a, Klf5

behavior

GO:0007610 2.22E-03 3

0.3

484

Cck, Sncg, Sepp1

cellular component movement

GO:0006928 2.69E-03 3

0.3

518

Cck, Vav3, Sema5a

process

organization
anatomical structure formation
involved in morphogenesis

Our gene expression profiling experiments revealed that PPARγ is highly
transcriptionally active in the lentiviral expression system in NIH3T3 fibroblasts,
and

that

it

regulates

genes

that

have

previously

been

identified

as

its

transcriptional targets. These genes are functionally involved in known PPARγregulated pathways including adipogenesis, lipid and carbohydrate metabolism,
mitochondrial function and cell proliferation/cell death. The number of genes
induced by rosiglitazone was also consistent with previous studies done in the
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NIH3T3 and the adipocyte 3T3-L1 cell lines. In addition, no unexpected biological
processes were enriched among the genes upregulated by PPARγ in these cells,
confirming that the lentivirus-transduced NIH3T3 cell line is a robust cell culture
model for studying PPARγ transcriptional activity.
By contrast, the E157D PPARγ regulated a much smaller number of genes
than the wild-type, even though the protein was equally abundant in the nucleus.
This loss of transcriptional function on PPARγ target genes that are required for
adipogenesis and metabolic homeostasis is the most likely cause of lipodystrophy
and diabetes in the E157D cohort. These findings contradict our original hypothesis
that the E157D mutation disrupts PPARγ transcriptional activity on a small subset of
its target genes, on which we would then focus as potential new candidate genes of
interest in diabetes pathogenesis. Instead, the mutation has a broad deleterious
effect on the vast majority of PPARγ target genes, presumably resulting in reduced
expression of genes regulating energy homeostasis and leading to metabolic
disease.
From the clinical perspective of diabetes, this result is not new or surprising the metabolic endpoints in the case of lipodystrophy caused by the E157D PPARγ
mutant are pathophysiologically similar to previously reported cases. The major
value of our findings is the discovery that a DNA-binding domain mutation can
severely reduce the transcriptional function of a nuclear receptor independently of
its ability to bind DNA. A similar mechanism of action of a nuclear receptor mutant
has never been described before, and these findings challenge the currently
accepted model of nuclear receptor domains as structurally and functionally
independent entities. In addition, the induction of non-PPARγ target genes by the
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E157D mutant raises the intriguing possibility that this gain-of-function activity is
causing the atypical clinical presentation in this mutant PPARγ cohort compared
with previously reported type III lipodystrophy cases.
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8 CHARACTERIZATION OF NOVEL PPRES NEAR E157D
PPARγ GAIN-OF-FUNCTION GENES
8.1

Loss-Of-Function And Gain-Of-Function Promoters Contain
Similar Numbers And Types Of PPREs.
In order to better understand the mechanisms underlying target gene

misregulation by E157D PPARγ, we sought to determine whether the mutant
receptor activates the “gain-of-function” genes from typical PPREs. We have already
established that the mutation does not affect the affinity of PPARγ for typical PPREs
in our gel shift assays. But it is possible that this DNA-binding domain mutation
could allow PPARγ to regulate the “gain-of-function” genes from non-DR1 DNA
sites. If so, the “gain-of-function” set of genes would be expected to contain fewer
DR1 PPREs than the “loss-of-function” set.
To answer this question, we identified putative PPREs in the promoter of
genes from the gain-of-function and the loss-of-function sets using MatInspector.
74% of the gain-of-function promoters and 68% of the loss-of-function promoters
contained DNA sequences matching the PPRE matrices defined by previous ChIPon-chip and ChIP-seq studies (Figure 20 A, [19, 20]). Fisher’s exact test generated
a p value of 0.2 for the comparison, indicating that the two sets of promoters are
not different with regard to putative PPRE content.
To compare the PPREs from the gain-of-function promoters to the PPREs
from the loss-of-function promoters, we loaded the putative PPRE sequences
identified by MatInspector into the MatDefine function of Genomatix. Positionweight matrices for the two sets of PPREs were similar, indicating that there is no
readily apparent inherent difference between the sequences of the PPREs in these
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two sets of genes (Figure 20 B). These findings are consistent with our previous
observations that the E157D PPARγ mutation does not alter the binding site
sequence selectivity of the receptor. Rather, it binds the same types of PPREs as
the wild-type, but has vastly different transcriptional activity, possibly through a
disruption in the way the protein interacts with the DNA once it is bound to the
promoter.

Figure 21. Putative PPREs Identified in the Promoters of Gain-of-Function and
Loss-of-Function Genes.
A, MatInspector position-weight matrices identified in 3T3-L1 adipocytes by ChIPon-chip and ChIP-seq studies were used to identify PPREs in the promoters of
genes. B, MatDefine position-weight matrices of the PPREs identified in the gainof-function (GF) and loss-of-function (LF) gene promoters.
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8.2

E157D PPARγ Has Increased Affinity for Weak PPREs in
Gain-Of-Function Gene Regulatory Regions.
In order to characterize the dynamics of the wild-type and E157D PPARγ on

gain-of-function gene promoters, we selected two of the putative PPREs identified in
this set of promoter for in-vitro studies of DNA binding and transcription induction.
Recent ChIP-seq studies have shown that PPARγ binding sites occur at many points
along its target genes, as well as at extended distances from their promoters and 3’
UTRs [21]. We therefore scanned genomic sequences from -10000 of the
transcription start site to 10000 downstream of the transcription termination of
each gene for putative PPREs using RVista 2.0. This highly permissive scan
identifies any sequence that resembles the V$PPARG.02 and V$PPARG.03 matrices,
defined above, and resulted in as many as a hundred putative PPREs per gene
entry. Reasoning that functionally important PPREs are likely to be conserved
across species, we eliminated the majority of the putative PPRE sequences from the
mouse genome because they were not conserved and aligned in the human. Finally,
we selected the PPREs from two genes whose products are involved in neuron
development, one of the gene ontology categories that were enriched in the gainof-function set of genes: synuclein gamma (Sncg) and microtubule associated
protein 2 (Mtap2).
As shown in Figure 21 A, the SNCG PPRE is located approximately five
thousand base pairs upstream of the transcription start site of the gene, in the
intron of a neighboring gene, and is highly conserved between the human and
mouse. Notably, previous ChIP-seq studies have demonstrated PPARγ binding to
the chromatin region containing the SNCG PPRE in mouse adipocytes [20, 140].
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The MTAP2 PPRE is located within the first translated exon of the gene. This PPRE
was identified by MatInspector and matched both the V$PPARG.02 and V$PPARG.03
matrices (core sequences indicated in Figure 21 B), and also is highly conserved.
Upregulation of Sncg and Mtap2 by rosiglitazone in NPγ2 E157D cells was confirmed
by qPCR (Figure 21 A and B). Basal expression of Sncg was increased nearly threefold in NPγ2 E157D cells compared with WT, and further induced approximately sixfold by rosiglitazone treatment. Mtap2 was expressed at similar levels in the wildtype and E157D NPγ2 cells, but was upregulated to almost three times higher level
by rosiglitazone in the mutant cell line. Both genes were not regulated by
rosiglitazone in the wild-type cell line, confirming their status as gain-of-function
genes for the E157D PPARγ.
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Figure 22. Putative PPREs in Gain-of-Function Promoters.
Genomic locations of putative PPREs near (A) Sncg and (B) Mtap2 genes are
shown. Gene expression in NPγ2WT and E157D (MUT) cell lines was confirmed by
qPCR. The core DR1 PPRE sequence is shown in bold-face in the mouse-human
alignments.
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To assess the novel putative PPREs for PPARγ binding, we used biotinylated
oligonucleotides
TGGAGGAAACC

containing

each

PPRE

AAAGCAAAGGTTA

and

flanking

GGAATTTT;

nucleotides

MTAP2:

(SNCG:

TTGGGGAGCAC

AGGTCACAGGGCA CCTATTCA) in a gel shift assay with nuclear extracts from
NIH3T3 cells transfected with either wild-type or E157D PPARγ2. Equal expression
of the wild-type and mutant PPARγ used in these assays was confirmed on a
Western blot (Figure 22 C). Shown in Figure 22 A, both the wild-type and mutant
proteins shifted the SNCG probe band, indicating PPRE binding, but the E157D
PPARγ bound more probe than the wild-type PPARγ. The specificity of binding was
confirmed by competition with a 200-fold excess of unfolded probe, which
abrogated the shifted band, and with a flag antibody, which resulted in a supershifted band. The MTAP2 PPRE was also shifted by both wild-type and E157D
PPARγ, with a higher intensity shifted band produced by the mutant than the wildtype, and with a high specificity demonstrated by cold probe competitor and
supershift (Figure 22 B). These data suggest that both the SNCG and the MTAP2
PPREs discovered by our bioinformatic approach are bona-fide PPARγ binding
elements that may have a higher affinity for the E157D PPARγ than the wild-type.
To rule out the possibility that stronger PPRE binding by the mutant receptor
is due to an artifact of nuclear extract collection, we compared the shifted bands
produced by the SNCG and MTAP2 PPREs to the consensus PPRE (AATGGTGGGC
AAAACT AGGTCA A AGGTCA TGAGGTGGA) and the ADN PPRE (CAGCAACA
GAAGAT GGGGCA A AAGTCA AAACCACAGCAGGA) as controls. Shows in Figure
22 d, E157D PPARγ bound the consensus and ADN probes equally well as the wildtype receptor, consistent with our previous experiments. By contrast, the mutant
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produced a much stronger intensity shifted band with the SNCG and MTAP2 probes
than the wild-type, confirming that these may be naturally weak PPREs and that the
E157D mutation allows PPARγ to binds them with increased affinity.

Figure 23. Gel-Shift Assays of PPARγ Binding to Novel PPREs.
Nuclear extracts from CHO cells transfected with the indicated plasmids were
incubated in binding reactions with (A) SNCG or (B) MTAP2 PPREs. C, Equal
expression of wild-type and E157D PPARγ was confirmed on a western blot. D,
Gel-shift was done as in A and B with the indicated PPREs as probes.

We assessed the ability of the SNCG and MTAP2 PPREs to drive transcription
of a luciferase reporter gene in a reporter plasmid construct similar to the ones we
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used previously to study well characterized PPREs. Shown in Figure 23, the ARE6
PPRE was transcriptionally active in the presence of the wild-type and less so with
the mutant PPARγ, confirming the validity of the assay. However, neither of the
newly identified PPREs alone was able to induce transcription in the context of the
heterologous promoter, either through the wild-type or E157D PPARγ. There was a
slight suppression of reporter transcription by both the wild-type and mutant
receptors from the SNCG PPRE, and the mutant, but not the wild-type PPARγ
suppressed transcription from the MTAP2 PPRE. These minor reductions in
transcription could be due to a nonspecific effect of PPARγ presence in the nucleus,
such as driving coregulators of transcription away from the reporter gene, rather
than a PPRE-dependent suppression of transcription. The results of these
transcription reporter studies indicate that the SNCG and MTAP2 PPREs are
transcriptionally inactive in the context of a heterologous promoter. However, this
does not rule out the possibility that E157D PPARγ is transcriptionally active on
these PPREs in vivo, as endogenous promoters may contain additional transcription
factor

binding

sites

transcriptional activity.

and

other

regulatory

elements

that

enhance

PPARγ

80

Figure 24. SNCG and MTAP2 PPREs Are Not Transcriptionally Active in
Heterologous Promoters.
NIH3T3 cells were transfected with luciferase reporter plasmids containing the
indicated PPRE, and the wild-type or E157D PPARγ expression plasmid, or the
empty vector. Means and standard errors of three independent experiments are
shown. *, p<0.05 determined by two-way ANOVA with post-hoc Bonferroni tests.
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9 E157D ENHANCES PPARγ INTERACTION WITH
TRANSCRIPTION COREPRESSORS
9.1

Existing Evidence of DNA as an Allosteric Regulator of
Nuclear Receptors.
Our findings so far have outlined a novel mechanism by which the E157D

PPARγ mutation causes lipodystrophy and metabolic syndrome. We have shown
that this conservative DNA-binding domain mutation, which directly contacts the
PPRE, does not affect the affinity of PPARγ for typical PPRE sites, but reduces its
ability to activate transcription of the majority of its target genes in a non-dominant
negative manner. The disruption must involve a step in the transcriptional
activation process that occurs after DNA binding. The major role of PPARγ in this
process, once it is bound to the PPRE, is to recruit transcription coregulators to the
DNA, which results in chromatin remodeling and regulation of transcription initiation
complex assembly. We therefore proposed a new working hypothesis that the
E157D mutation alters the interaction of PPARγ with transcription coactivators
and/or corepressors, leading to reduced transcription of its target genes.
The novelty of such a mechanism lies in its implication of a functional
interaction between the DNA binding and ligand binding/activation domains of the
nuclear receptor. These two domains, located on opposite ends of the receptor
molecule, have previously been thought to be completely independent of each other
by way of the flexible hinge domain separating them. However, recent x-ray
crystallography and nuclear magnetic resonance studies of nuclear receptor
structure have challenged this view, showing that the glucocorticoid receptor and
the retinoid X receptor assume a slightly different conformation when bound to
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their respective DNA site than when free in solution [141, 142]. This new structural
evidence suggests that the DNA molecule can be considered an allosteric regulator
of nuclear receptor structure, affecting not just the DNA binding domain but
inducing structural shifts in the entire protein. Moreover, the x-ray studies of the
glucocorticoid receptor demonstrate that the DNA-bound receptor structural shifts
are specific to the DNA sequence to which the receptor is bound, indicating that the
interaction between the DNA and the receptor is informed by the specific sequence
of the binding site. In turn, we have shown that different PPRE sequences influence
the behavior of E157D PPARγ in different ways, ranging from extremely to mildly
defective, to overactive. Given the position of glutamate 157, we predict that this
variability can be explained by the specificity of its spatial position within each PPRE
sequence and the effect of that interaction on the structure of the entire receptor.
Finally, the glucocorticoid receptor studies also showed that the subtle structural
changes in the receptor on different DNA binding sequences were functionally
significant,
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coregulator complexes recruited by the E157D PPARγ, influenced both by the
receptor mutation and by the PPRE sequence to which it is bound, and resulting in
changes in its transcriptional activity.

9.2

Nuclear Receptor Corepressors Suppress E157D PPARγ
Activity More Than Wild-Type.
In order to assess the interaction of E157D PPARγ with transcription

coregulators, we measured the transcriptional activity of the wild-type and mutant
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receptors using the luciferase reporter assay in the presence of increasing amounts
of various coregulators. Shown in Figure 24 (left panel), the transcriptional activity
of the wild-type PPARγ on the aP2 promoter was suppressed in the presence of
increasing amounts of SMRT until it reached a plateau of approximately 70% of its
basal activity level. E157D PPARγ was also suppressed by SMRT, and its plateau
level was significantly lower than that of the wild-type, at approximately 40% of
maximal transcription. As expected, SMRT did not suppress the activity of wild-type
or mutant PPARγ in the presence of saturating levels of rosiglitazone (data not
shown). Similarly, increased amounts of NCoR1 reduced the basal but not the
rosiglitazone-stimulated transcriptional activity of PPARγ (Figure 24, right panel).
As with SMRT, there was a significant difference between the maximal suppression
level of the wild-type and E157D PPARγ transcriptional activity on the aP2
promoter, with the mutant receptor activity being suppressed more effectively by
the corepressor. Increased variability in this experiment resulted in loss of
statistical significance at the maximal suppression level, but the difference between
the suppression curves for the wild-type and mutant PPARγ is significant.
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Figure 25. Suppression of Wild-Type and E157D PPARγ Transcriptional Activity by
nuclear receptor corepressors.
NIH3T3 cells were transfected with the wild-type (circles) or E157D (squares)
PPARγ, increasing amounts of the indicated corepressor protein, and the aP2
luciferase reporter plasmid. Insets show suppression curves for, and bar graphs
represent maximal suppression by each corepressor. Data are means and
standard errors of three independent experiments. *, p<0.05 determined by twoway ANOVA.

These data suggest that the E157D mutation generally renders PPARγ more
vulnerable to suppression by transcription corepressors. In the context of our
alternative model of nuclear receptor activity, the mutant receptor interaction with
certain PPRE sequences may result in structural rearrangements which make the
corepressor binding surfaces of the mutant more exposed than the wild-type
receptor. Interestingly, in the presence of saturating concentration of rosiglitazone
and large amounts of NCoR1, E157D PPARγ failed to increase transcription to the
same extent as the wild-type (data not shown). The increase in PPARγ
transcriptional activity in this environment is most likely due to increased
availability of transcription coactivators as a result of wide-spread suppression of
gene transcription in the cell. Reduced activity of the mutant in these experiments
indirectly implies that the mutant PPARγ interacts less effectively with the
transcription coactivators that become increasingly available when transcription in
the cell is non-specifically suppressed by NCoR1. Thus, even though we have not
identified a coactivator that directly enhances PPARγ transcriptional activity in our
transfected system, there is indirect evidence that the E157D mutation reduces the
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ability of PPARγ to effectively interact with transcription coactivators when bound to
certain PPRE sequences. Overall, these results support our proposed model in which
the DNA binding site allosterically and specifically regulates PPARγ transcriptional
activity by altering its coregulator interaction surface structure, and this effect is
disrupted by the E157D mutation.
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10 DISCUSSION
10.1

Molecular Characterization of E157D PPARγ.

We have characterized the molecular mechanisms of action of a novel PPARγ
mutant, E157D, which causes lipodystrophy and severe insulin-resistant diabetes in
a human cohort. This mutation, located at the interface of PPARγ and the DNA
molecule, works through a previously unreported mechanism in which DNA binding
is mostly unaffected, yet activation of target gene transcription is severely impeded
on the majority of PPARγ-regulated promoters.
The mutant PPARγ demonstrated a small, but consistent increase in DNA
binding affinity in our gel-shift dose-response assays (Figure 14). Because the
mutated residue is shorter than the wild-type, and protrudes directly into the major
groove, it is possible that helix 1 of the mutant receptor inserts itself deeper into
the major groove of the PPRE. Such a change may be proposed to result in a more
favorable binding state due to replacement of more water molecules, a major
driving force in protein-DNA interactions [143]. But we have clearly shown a lack of
any dominant negative effect in transcription assays (Figure 11), so it is unlikely
that this slightly increased DNA binding affinity results in blocking the PPRE through
reduced promoter recycling. This difference is more likely to be negligible or very
small.
Not all PPARγ target transcripts are equally affected by this mutation, and
the changes in transcriptional activity include a gain of function on some genes that
are not regulated by the wild-type PPARγ, while a small number of PPARγ-regulated
transcripts remain unaffected by the E157D mutation. There are multiple factors
besides the PPRE sequence that determine PPARγ transcriptional activity on a given
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DNA site. Cell type, endogenous versus overexpressed promoters, native versus
heterologous constructs are all important variables that affect transcriptional
readouts. By reducing the varied DNA binding site to just the PPRE sequence, we
demonstrated that the E157D mutation affects PPARγ transcriptional activity by
disrupting a regulatory function that is intrinsic to the sequence of the PPRE.
Expanding the region to include whole promoters and endogenous chromatin, we
showed that other DNA-associated factors play a role in the effect the mutation has
on the receptor function. Finally, taking the whole-genome approach allowed us to
identify networks of genes that are misregulated by the mutant.
The results of our transcription reporter assays should not be generalized to
other tissues and molecular contexts: the exact set of genes that is misregulated by
E157D PPARγ in NIH3T3 cells is not expected be also similarly affected in human
tissues. In fact, even in our transiently-transfected model system, the effect of the
mutation was completely reversed on a full-promoter aP2 reporter construct
compared with the isolated PPRE from the aP2 gene (Figure 9). Rather than directly
translating our findings into the clinical scenario, they should be considered a
general proof of concept that the E157D PPARγ mutation alters the way it interacts
with DNA binding sites and results in various transcriptional changes. The “gain of
function” genes in our transgenic cells likely share a common feature that allows
the mutant receptor to bind and induce transcription more effectively than the wildtype, and the same is likely to be true in the human tissues, but the precise set of
these transcripts may be different. Overall, our findings underscore the importance
of glutamate 157, and likely the p-box in general, in the interaction with the DNA
binding site, beyond simply acting as an anchor for PPARγ.

88

10.2

Comparisons with Other Known P-Box Mutants.

Overall, it is clear that not all amino acids in the p-box of nuclear receptors
play an equal role in the receptor function. The two cysteines participate in
coordinating the zinc atom and required for the correct folding of the zinc finger
structure, and are therefore necessary for DNA binding. This is evidenced by
numerous reports of naturally-occurring or site-directed cysteine mutations which
abolish DNA binding, resulting in complete loss of function of the receptor [62, 144147]. However, the other four amino acids in the p-box have a more subtle role and
are known to be important for DNA binding site discrimination. For instance,
replacing just two amino acids in the p-box of the thyroid hormone receptor to
make it identical to the glucocorticoid receptor p-box sequence completely redirects
the DNA binding site preference of the receptor, abolishing thyroid hormone
response element binding and rendering the mutant receptor able to bind and
activate glucocorticoid response elements [148].
E157D is the first reported naturally-occurring p-box mutation in PPARγ, but
other nuclear receptors in which similar mutations have been reported include
steroidogenic factor 1 (SF-1) and photoreceptor-specific orphan nuclear receptor
NR2E3 (Table 6). The latter involves an in-frame deletion of three p-box amino
acids including a zinc coordinating cysteine, resulting in disruption of the zinc finger
structure. DNA binding is abolished by this p.N65_C67del NR2E3 mutation, causing
a rare retinal disorder in humans called autosomal-recessive enhanced S-cone
syndrome. Two SF-1 p-box mutants have been reported in the human population:
C33S and G35E. The former one disrupts the zinc coordination lattice, similarly to
p.N65_C67del in NR2E3 and C190S in PPARγ [62, 149], resulting in complete loss
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of DNA binding and transcriptional activity. This mutation causes 46, XY partial
gonadal dysgenesis and underandrogenization [150].
The G35E mutation, however, preserves the zinc-finger folding of the DNA
binding domain, and disrupts its binding to most SF-1 response elements, while still
maintaining the ability to bind a certain subset of the DNA sequences [151, 152].
Glycine 35 of SF-1 is equivalent to glycine 161 of PPARγ, located on the same
aspect of the a-helix as glutamate 157, and facing the major groove of the DNA
molecule. The variability in SF-1 binding to target DNA sites when this glycine is
mutated to a glutamate reflects the importance of various DNA sequences in the
way the receptors interacts with the DNA. Binding to non-SF-1 response elements
was not investigated, but is an intriguing possibility given that this mutant is
transcriptionally active on a subset of its target sites. Furthermore, 46XY humans
heterozygous for G35E SF-1 have the added clinical feature of adrenal failure, in
addition to the sex-reversal caused by the complete loss-of-function SF-1 C33S
mutant. If the G35E mutation causes SF-1 to recognize and non-SF-1 target sites
and regulate transcription of a different gene network, the adrenal failure could be
a result of this added activity. This hypothesis parallels our own model in which
E157D, a non-cysteine p-box mutation interfacing with the DNA major groove,
gains

transcriptional

activity

on

weak

PPREs

and

leads

to

non-classical

lipodystrophy features in the human cohort.
A chance discovery lead to the identification of the D69A mutation in the
HNF4 gene in multiple sources of the human hepatoma HepG2 cell line [153].
Although not found in a human population, this mutant is of particular interest to us
as it involves the amino acid that is the equivalent of glutamate 157 in PPARγ. Even
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though aspartate 69 is a highly conserved residue in the HNF4 gene, replacing it
with an alanine has only a mild effect on its transcriptional activity on known HNF4regulated promoters. Specifically, the D69A HNF4 mutant retains full transcriptional
activity in reporter assays from a classic HNF4 target promoter, and showed an
increased activity on several other promoters. DNA binding site discrimination by
this mutant was not investigated in more detail.

Table 6. Naturally-Occurring Nuclear Receptor P-Box Mutations Reported to Date.
Nuclear
receptor

Molecular

mutation

P-box change

Clinical presentation

mechanism

Ref.

SF-1 G35E

wt:

Adrenal failure and complete

Impaired DNA

[151,

mut: CESCKE

46XY sex-reversal

binding

152]

wt:

46XY partial gonadal

No DNA binding

[150]

No DNA binding

[149]

Increased activity on

[153]

SF-1 C33S

CESCKG
CESCKG

mut: CESSKG

dysgenesis and
underandrogenization

NR2E3

wt:

CNGCSG

p.N65_C67del

mut: C___SG

enhanced S-cone syndrome

HNF4 D69A

wt:

HepG2 cell line mutant

CDGCKG

mut: CAGCKG

Autosomal-recessive

select promoters

These studies, together with the ones discussed in the background section,
have shaped our understanding of the way nuclear receptors discriminate between
DNA sequences and the specific roles of p-box amino acids in this process. Although
limited in number and mechanistic scope, studies of nuclear receptor p-box mutants
are testaments to the complexity and subtlety of receptor-DNA interaction. Our
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studies of the E157D PPARγ mutant reveal a deeper importance of the p-box in
mediating fine-tuned transcriptional activity changes on various PPRE sequences.

10.3

DNA Binding Site as an Allosteric Regulator of Nuclear
Receptor Activity.

Since the domain structure of nuclear receptors has been described, the DNA
binding domain has been traditionally understood as an independent moiety from
the ligand-binding and transactivation functions that are separated from it by a
flexible hinge. This classic model treats the DNA binding domain as little more than
an anchor, able to recognize and specifically bind various versions of a consensus
DNA sequence, while the transcriptional regulation activity was carried out by the
ligand-binding domain. While the major functional roles of each domain are
accurately explained by this model, it fails to address the significance of subtle
variations in DNA binding site sequences that have evolved to regulate gene
expression. Tissue-specific nuclear receptor activity has been attributed largely to
coregulator make-up, and with the regard to PPARγ, much work has been done to
characterize the activity of various natural and synthetic ligands. Crystallizing whole
nuclear receptor molecules for x-ray imaging has proved to be technically
challenging, leading to a shift in the research of nuclear receptor structure and
function to the isolated ligand-binding domains. As a result, relatively little
advancement has been made in the past several decades in our understanding of
the nuclear receptor-DNA interactions on a structural level.
Contrary to the conventional nuclear receptor domain model described here,
our understanding of the general interactions between proteins and DNA implies
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that there are reciprocal changes in structure imposed by binding. DNA bending by
proteins that specifically bind to major grooves has been characterized in detail and
shown to be categorically different and more severe than the slight changes caused
by non-specific binding of proteins to minor grooves [154]. The major groove DNA
distortion occurs in a sequence-specific manner and implies that the structure of
the DNA-bound protein may also be altered to adjust to the binding state. In the
case of nuclear receptors, this may result in DNA sequence-dependent regulation of
coregulator complex recruitment mediated by structural changes in the DNAbinding domain and propagated to the ligand-binding and activation domains.
Several recent studies have revealed that the DNA binding domain and the
DNA binding site may play a more important role in regulating the transcriptional
activity of nuclear receptors than previously recognized. The x-ray crystal structure
of the full-length PPARγ-RXRα heterodimer bound to the consensus PPRE molecule
has shown that the DNA-binding domain of PPARγ makes extensive energyfavorable contacts with various regions of RXRα, suggesting that it contributes to
heterodimer formation and transactivation of the complex [84]. Discrete structural
rearrangements in the holoprotein RAR when free in solution versus bound to its
DNA response element have been shown by NMR spectroscopy [142]. Crystallizing
the glucocorticoid receptor homodimer on several known glucocorticoid response
elements, Dr. Yamamoto and colleagues have shown that the receptor holoprotein
assumes slightly different conformations on different DNA sequences [141]. These
structural changes result in variations in the coregulator interaction surfaces that
are exposed when the receptor is bound to different DNA sequence, and lead to
recruitment of different compositions of coregulator complexes onto the DNA.
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All of these recent observations suggest that the significance of the DNA
binding site to nuclear receptor function is beyond merely that of an anchoring site.
The interaction between a nuclear receptor and the DNA molecule is a complex
process involving reciprocal structural changes in both partners and is ultimately
reflected in the transcription coregulator recruitment process. In this emerging new
model of nuclear receptors, the DNA molecule is thought of as an allosteric
regulator of nuclear receptor transcriptional activity via the DNA binding domain,
much like the specific ligands that regulate its activity at the ligand binding domain.
In this way, fine-tuned transcriptional regulation of gene networks in achieved by a
combination of many factors including the specific ligand, the DNA binding site
sequence, and the transcriptional co-regulator abundance in the cell [155]. Our
detailed analysis of the E157D PPARγ mutant supports the role of DNA as an
allosteric regulator of PPARγ function. The PPRE sequence-dependent transcriptional
activity of the mutant, compared with the wild-type, suggests that the p-box
substitution plays a greater role on some PPREs than others. These findings indicate
that not all PPRE sequences behave the same when bound to PPARγ, and the
differences in transcriptional activity of the mutant on various PPREs are most likely
explained by structural changes induced by these binding sites.

10.4

Implications for Nuclear Receptor Gene Evolution.

The discovery of differential nuclear receptor structure and behavior on
different DNA binding sequences indicates that the diversity in nuclear receptor
binding sites is non-trivial and may have regulatory significance for nuclear receptor
transcriptional activity. The nuclear receptor superfamily has evolved from an
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ancient common nuclear hormone receptor ancestor that is present in all bilateria
[156]. One of the earliest indications that p-box and PPREs co-evolved came from
the mutational analysis study which identified the

p-box amino acids as

determinants of nuclear receptor binding site selectivity [14]. By showing that
replacing the p-box of the glucocorticoid receptor with that of the thyroid hormone
receptor causes the chimeric receptor to bind and activate transcription from
thyroid

hormone

DNA

response

elements,

the

authors

provided

a

simple

explanation for the co-evolution of nuclear receptors and hormone-responsive gene
networks. Conversely, mutating the p-box of thyroid hormone receptor to mimic
that of the glucocorticoid receptor (the GS125 mutation) enables the thyroid
hormone receptor to recognize, bind and regulate transcription from GREs while
abolishing TRE binding [148].
Recent advances in gene sequencing have enabled sequence conservation
analyses across a wide array of species. The Mutual Information method was
recently used to analyse co-evolving pairs of amino acids in PPARγ and RXRα with
the goal of highlighting amino acid residues most important for specific DNA binding
[157]. This study revealed that the PPARγ:RXRα heterodimerization interface, as
well as the C-terminal extension of the DNA binding domain which binds the minor
groove of the DNA in the 5’ PPRE flanking region, are both highly co-evolved and
may be important for binding site recognition. The minor groove contact had
previously been shown to play a role in DNA binding, both by PPRE sequence
analysis [49] and crystal structure [84]. One proposed mechanism driving the coevolution of DNA response elements and DNA binding interfaces of nuclear
receptors involved conservation of the response element sequence and the cDNA
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sequence of the nuclear receptor region that binds there [158]. Although this has
only been demonstrated for the glucocorticoid receptor, one possibility is that
nuclear receptor DNA recognition surfaces may preferentially bind DNA sequences
that are identical to their cognate codons.
Our genome-wide study of E157D PPARγ transcriptional activity has identified
a set of genes, some of which are functionally related, that are activated by the
mutant receptor but not by the wild-type. Previous studies of PPARγ binding sites
suggest that the wild-type PPARγ binds to PPREs in the vicinity of some of those
genes. In the context of PPARγ and PPRE evolution, our findings indicate that these
“gain-of-function” genes represent a gene network that co-evolved to have PPREs
that weakly bind PPARγ. The E157D substitution disrupts this evolutionary process
and makes PPARγ more active on these weak PPREs, and conversely makes it less
active on stronger PPREs, changing the gene network regulated by this receptor
and leading to atypical type III lipodystrophy.
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11 FUTURE DIRECTIONS
11.1

Elucidate the Structural Features of PPARγ Interaction
With Various PPREs.

At the heart of the allosteric DNA regulation model is the concept of subtle
structural changes in the nuclear receptor upon binding to various DNA sequences.
X-ray crystallography and, more recently, nuclear magnetic resonance have been
used to study nuclear receptors bound to their respective DNA recognition sites,
and specifically to demonstrate structural changes in the glucocorticoid receptor
and RXR [141, 142] when bound to various DNA sequences. Both of these methods
have the necessary sensitivity to detect slightly different positioning of the
coregulator interacting surfaces, the functionally important outcome of allosteric
regulation by DNA. But positional changes in the PPARγ protein when bound to
PPREs have not been investigated to date.
The E157D mutation provides an opportunity to determine the role of the pbox in structural interactions between the protein and DNA. Our plans for the near
future include resolving the structures of the wild-type and E157D PPARγ bound to
several known PPREs. We predict that PPARγ, similarly to other nuclear receptors,
will assume a slightly different conformation when bound to DNA than when free in
solution. Furthermore, the positioning of coactivator interaction surfaces is
predicted to be specific for each PPRE sequence, as has been shown for the
glucocorticoid receptor [141]. The E157D mutation is predicted to have a variable
effect on these structural relationships, resulting in variable disruptions in
coregulator surface arrangement.
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11.2

Characterize the Composition of Transcription Coregulator
Complexes on Various PPREs.

To confirm that the PPRE sequence guides the recruitment of transcription
coregulators to the promoter, we plan to carry out co-precipitation experiments to
compare the amounts of known nuclear receptor corepressors and coactivators that
bind PPARγ on different PPREs. This interaction will be tested in vitro using biotinlabeled PPREs and nuclear extracts containing transfected PPARγ, NCoR1 and SMRT
proteins. The binding reaction will be carried out similarly as in the gel-shift
experiment, with the addition of nuclear receptor corepressors after the PPARγPPRE complex has formed. The entire bound complex will then be precipitated by
streptavidin-linked magnetic beads, washed and eluted. The amounts of coregulator
molecules co-precipitated with the wild-type and E157D PPARγ on different PPREs
will be compared on a Western blot. The results from this in vitro study will reveal
whether there is indeed an intrinsic regulatory interaction between the PPRE and
PPARγ that instructs the recruitment of coregulator molecules to the DNA binding
site in a sequence-specific manner.
To test the validity of this model in the context of native chromatin, and any
effect of DNA structure and chromatin-associated proteins, the promoter occupancy
of various endogenous nuclear receptor coregulators at known PPARγ binding sites
will be determined using chromatin immunoprecipitation. In addition, this method
will be used to measure histone modifications at these sites as the functional
outcome of differential coregulator recruitment. Commonly measured histone
marks, such as H3K4 and H3K27, may emerge as the mechanistic step mediating
the

transcriptional

effects

of

PPRE-directed

recruitment

of

transcription
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coregulators. Finally, by comparing these measurements in cells expressing wildtype and E157D PPARγ, the role of the p-box in the PPRE-PPARγ interaction
proposed here will be confirmed in both the in-vitro and in-vivo models.

11.3

Analyze the Regulatory Regions of PPARγ-Inhibited Genes
For Putative Negative PPREs.

Our genome-wide transcriptional activity studies revealed a set of genes
involved in inflammation and the immune response that were downregulated by
PPARγ in a ligand-dependent manner (Figure 19). Inhibition of inflammatory genes
by PPARγ has been widely recognized, but this activity is poorly understood on the
molecular level, and it is possible that downregulation of these genes is mediated
by indirect factors upon PPARγ activation. However, direct ligand-dependent gene
inhibition by the glucocorticoid receptor has been demonstrated on “negative GREs”
[159]. These response elements have unique sequence features that differentiate
them from previously defined GREs with positive transcription regulation activity.
Negative PPREs have not been reported to date. Our results provide an opportunity
for bioinformatic identification of putative negative PPREs which may mediate the
downregulation of inflammatory genes by PPARγ.
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PPARγ is a nuclear receptor that plays a central role in metabolic regulation
by regulating extensive gene expression networks in adipose, liver, skeletal muscle
and many other tissues. Human PPARγ mutations are rare and cause a
monogenetic form of severe type II diabetes with metabolic syndrome, known as
familiar

partial

lipodystrophy

lypodystrophy.
in

a

large

The

E157D

Canadian

PPARγ

kindred,

mutant

presenting

causes

atypical

with

multiple

musculoskeletal, neurological and hematological abnormalities in addition to the
classic lipodystrophy features of insulin-resistant diabetes, hypertension and
dyslipidemia. This mutation is localized to the p-box of PPARγ, a small region that
interacts directly with the DNA molecule and is required for DNA binding site
specificity. Mechanistic analysis revealed that E157D PPARγ binds PPARγ response
elements (PPREs), but is mildly, moderately or severely defective at inducing
transcription from most promoters, without dominant negative activity. This
suppression of transcriptional activity may be mediated by an increased effect of
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nuclear receptor corepressors on E157D PPARγ. In addition, the mutant binds
atypical PPREs in the regulatory regions of a small set of genes outside of the
PPARγ-regulated network, and induces transcription of these genes. The loss of
transcriptional activity on PPARγ-regulated promoters leads to the metabolic
disease in the E157D PPARγ cohort, while the gain of activity on non- PPARγ target
promoters may explain the atypical clinical presentation associated with this
mutation. The misregulation of target genes by this DNA-contacting mutant
highlights a previously under-appreciated importance of the DNA molecule as an
allosteric regulator of the transcriptional activity of nuclear receptors. In summary,
this dissertation describes a human PPARγ mutation that works through a novel
mechanism to cause atypical lipodystrophy, and provides support for a more
integrated view of the nuclear receptor-DNA interaction and transcription activation.
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